Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
1 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  A PHASE 2 RANDOMIZED, DOUBLE -BLIND, PLACEBO -CONTROLLED  TRIAL  TO 
ESTABLISH THE EFFICACY AND SAFETY  OF ONCE WEEKLY ORAL 
AMINOPTERIN FOR THE TREATMENT OF SUBJECTS WITH MODERATE -TO-
SEVERE  PSORIASIS  
 
 
Syntrix Protocol AMT -PSO-201 
 
Protocol Version: 1.8 
01 December  2018 
 
Study Agent:   LD-Aminopterin  0.5 mg tablets  
 
Protocol Number:  Syntrix -AMT -PSO-201 
 
IND Number:   71,205  
 
 
Sponsor:  Syntrix Biosystems, Inc.  
 
Personnel:   Stuart Kahn, MD (Project Director, Sponsor’s Medical Monitor)  
James McNamara, MD (NIAID Medical Monitor  and Independent Safety 
Monitor ) 
    John Zebala, MD, PhD (Regulatory Affairs)  
    Matt Johnson , MS  (Biostatistician)  
    Sandi Tennyson  (Data Manager)  
    Aaron Schuler, PhD (Formulation Scientist)  
    Kristi Garrett  (CMO Representative)  
     
 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280181]  
Dallas, [LOCATION_007] [ZIP_CODE]  
Tel: ([PHONE_19572]  Alan Menter , M.D.  
Tel: 972 -354-7993  
Email: alanmresearch @gmail.com  
Dermatology Associates  
[ADDRESS_1280182]  
Seattle, WA [ZIP_CODE] -1498  
Tel: ( 206) 267 -2100  
Fax: (206) 267 -2101  Peter Jenkin, MD  
Tel: (206) 267 -2100  
Email: pjenkin @daseattle.com  
Additional sites to be determined.   
 
Sponsor  
Syntrix Biosystems, Inc.  
[ADDRESS_1280183] NW  
Suite B5  
Auburn, WA  [ZIP_CODE]  
Fax:  253 -833-8127  
Stuart Kahn  
Tel: 206 -524-0214  
Alt Tel: 253 -833-8009 x32  
Mobile: 206 -330-7604  
Email: [EMAIL_17386]  John Zebala  
Tel: [PHONE_13147]  
Aaron Schuler  
Tel: 253 -833-8009   Kristi Garrett  
Tel: [PHONE_19573]  
 
NIH -NIAID  
Autoimmunity and Mucosal 
Immunity Branch  
Division of Allergy, Immunology 
and Transplantation  
NIAID, NIH  
[ADDRESS_1280184], 7D31  
Rockville, MD [ZIP_CODE]  James McNamara, MD  
Chief, Autoimmunity and Mucosal Immunity Branch  
Division of Allergy, Immunology and Transplantation  
Tel: (240) 627 -3517  
Email: [EMAIL_17387]  
 
  
Statistician   
DF/Net Research Inc.  
[ADDRESS_1280185]  
Seattle, WA  [ZIP_CODE]  
 Matt Johnson  
Tel: (206) 322 -5931  
Email: [EMAIL_17388]   
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
3 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Principal Investigator [INVESTIGATOR_911375]: Syntrix -AMT -PSO-[ADDRESS_1280186] this clinical study in accordance with the E6 Guidance of the International 
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) “Good Clinical Practice: Con solidated Guidance”, and the U.S. Code of Federal 
Regulations governing the protection of human subjects (21 CFR 50), Institutional Review Boards 
(21 CFR 56) and the obligations of clinical investigators (21 CFR 312). Furthermore, I agree to 
maintain all s tudy documentation for the time specified in this protocol.  
 
 
 
 
Principal Investigator [INVESTIGATOR_911376] -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
4 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Table of Contents  
Principal Investigator [INVESTIGATOR_65908]  ................................ ................................ ................................ ........  3 
Table of Contents  ................................ ................................ ................................ ................................ . 4 
Protocol Summary (Synopsis)  ................................ ................................ ................................ .............  9 
1 OBJECTIVES  ................................ ................................ ................................ .............................  11 
1.1 Primary Objective  ................................ ................................ ................................ ...............  11 
1.2 Secondary Objectives  ................................ ................................ ................................ ..........  11 
2 BACKGROUND AND SCIENTIFIC RATIONALE  ................................ ................................  11 
2.1 Introduction  ................................ ................................ ................................ .........................  11 
2.2 Description of the Study Agent  ................................ ................................ ...........................  12 
2.3 Relevant AMT Pre -clinical Studies ................................ ................................ .....................  13 
2.3.1  Adenosine Release In Vitro  ................................ ................................ .........................  13 
2.3.2  Mouse Anti -Inflammatory Studies  ................................ ................................ ..............  13 
2.3.3  L-AMT and D -AMT Pharmacokinetics and Toxicity in Dogs  ................................ .... 14 
2.3.4  Canine PK Study  ................................ ................................ ................................ ..........  15 
2.3.5  Canine Atopic Dermatitis (CAD) Pi[INVESTIGATOR_16116]  ................................ .............................  16 
2.3.6  CAD Dose Ranging Trial ................................ ................................ .............................  16 
2.4 Relevant Human AMT Clinical Studies ................................ ................................ ..............  17 
2.4.1  Psoriasis Subjects Exposed to Lederle’s L -AMT 0.5 mg Tablet  ................................ . 17 
2.4.2  Oncology Subjects Exposed to AMT in Multi -Agent Therapy (CINJALL trial)  ........  17 
2.4.3  CNS Sparing Relative to Systemic Compartments  ................................ ......................  18 
2.4.4  Oncology Subjects Exposed to AMT Monotherapy  ................................ ....................  19 
2.4.5  AMT Efficacy Experience in Psoriasis  ................................ ................................ ........  19 
2.4.6  Early (1951) AMT Efficacy Experience in RA  ................................ ...........................  19 
2.4.7  AMT Chronic (> 1 year) Toxicity Experience in Psoriasis and Oncology  .................  20 
2.4.8  Bioavailability  ................................ ................................ ................................ ..............  20 
2.4.9  Syntrix LD -AMT Tablets in PK Study in Psoriasis Subjects  ................................ ...... 20 
2.4.10  Syntrix LD -AMT Tablets in Phase 2 Study in RA Subjects  ................................ ....... 21 
2.5 Potential Risks and Benefits  ................................ ................................ ................................  21 
2.6 Rationale ................................ ................................ ................................ ..............................  22 
3 OVERVIEW OF INVESTIGATIONAL PLAN  ................................ ................................ ........  23 
3.1 Study Design  ................................ ................................ ................................ .......................  23 
3.2 Primary and Secondary Endpoints  ................................ ................................ ......................  23 
3.2.1  Co-Primary Efficacy Endpoints  ................................ ................................ ...................  23 
3.2.2  Secondary Efficacy Endpoints  ................................ ................................ .....................  23 
3.2.3  Primary Safety Endpoints  ................................ ................................ ............................  24 
3.2.4  Exploratory Endpoints  ................................ ................................ ................................ . 24 
3.3 Study Sites  ................................ ................................ ................................ ...........................  24 
3.4 Number of Subjects  ................................ ................................ ................................ .............  24 
3.5 Estimated Duration/Completion of the Study  ................................ ................................ ..... [ADDRESS_1280187] Replacement  ................................ ................................ ................................ ...........  29 
5 STUDY PROCEDURES  ................................ ................................ ................................ ............  29 
5.1 Consent and Screening Procedures  ................................ ................................ .....................  29 
5.2 Week 0 - Day 0 (Baseline) Evaluations  ................................ ................................ ..............  31 
5.3 Week 2 - Day 14 Evaluations (±2)  ................................ ................................ ......................  32 
5.4 Week 6 - Day 42 Evaluations (±3)  ................................ ................................ ......................  34 
5.5 Week 10 - Day 70 Evaluations (±3)  ................................ ................................ ....................  35 
5.6 Week 14 - Day 98 Evaluations (±3)  ................................ ................................ ....................  36 
5.7 Week 17 - Day 119 Evaluations (±4)  ................................ ................................ ..................  37 
5.8 Week 20 - Day 140 Evaluations (±4)  ................................ ................................ ..................  [ADDRESS_1280188] of Administration and Dispensing  ................................ ................................ ... 41 
7.5.3  Unused Study Drug  ................................ ................................ ................................ ...... 41 
8 ADVERSE EVENTS  ................................ ................................ ................................ .................  41 
8.1 Specification of Safety Parameters  ................................ ................................ .....................  41 
8.2 Definitions  ................................ ................................ ................................ ...........................  41 
8.2.1  Adverse Event  ................................ ................................ ................................ ..............  41 
8.2.2  Serious Adverse Event  ................................ ................................ ................................ . 41 
8.2.3  Unexpected Adverse Event  ................................ ................................ ..........................  42 
8.3 Assessment of Adverse Events  ................................ ................................ ...........................  42 
8.3.1  Severity Grading  ................................ ................................ ................................ ..........  42 
8.3.2  Relationship of Adverse Event to Study Drug  ................................ .............................  42 
8.4 Diaries (Memory Aids)  ................................ ................................ ................................ ....... [ADDRESS_1280189]  ................................ ................................ ...........  45 
9.1.1  Hematologic Adverse Events (Leukopenia, Thrombocytopenia, Anemia)  .................  45 
9.1.2  Hepatic Adverse Events  ................................ ................................ ...............................  45 
9.1.3  Mucositis/Stomatitis Adverse Events  ................................ ................................ ..........  46 
9.2 Criteria for Interrupting the Trial Based on Dos e-Limiting Toxicity (DLT)  ......................  [ADDRESS_1280190] Access to Source Data/Documents, Study Monitoring, Data Collection  .................  51 
11.4  Modification of the Protocol  ................................ ................................ ...............................  52 
11.5  Protocol Deviation(s)  ................................ ................................ ................................ ..........  [ADDRESS_1280191] Retention  ................................ ................................ ................................ .............  54 
11.11  Exclusion of Women, Minorities, and Children (Special Populations)  ..........................  [ADDRESS_1280192] Confidentiality  ................................ ................................ ................................ .... 54 
Appendix A: Schedule of Study Visits and Procedures ................................ ................................ ..... [ADDRESS_1280193]  
EMA    European Medicines Agency  
FDA    Food and Drug Administration  
FWA    Federal -Wide Assurance  
GCP    Good Clinical Practice  
GLP    Good Laboratory Practice  
GMP    Good Manufacturing  Practice  
HBV    Hepatitis B Virus  
hCG    Human Chorionic Gonadotropin  
HCV    Hepatitis C Virus  
HIPAA   Health Assurance Portability and Accountability Ac t 
HIV   Human Immunodeficiency  Virus  
HR    Heart Rate  
IB    Investigator’s Brochure  
ICF   Informed Consent Form  
ICH International Conference for the Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use  
IND   Investigational New Drug  
IRB   Institutio nal Review Board  
ISM   Independent Safety Monitor  
ITT   Intent -To Treat  
LOCF    Last Observation Carried Forward  
LOQ    Limit of Quantification  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
8 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  MDRI    Menter Dermatology Research Institute  
MedDRA   Medical Dictionary for Regulatory Activities  
MM   Medical Monitor  
MOP    Manual of Procedures  
N    Number (typi[INVESTIGATOR_19737])  
NDA    New Drug Application  
NIAID    National Institute O f Allergy and Infectious Diseases  
NIH   National Institutes of Health  
OHRP    Office for Human Research Protection  
OHSR    Office for Human Subjects Research  
PASI    Psoriasis A rea and Severity Index  
PE    Physical Exam  
PHI   Protected Health Information  
PI    [INVESTIGATOR_632043]#    Participant Identification Number  
QA    Quality Assurance  
QC    Qualit y Control  
RR    Respi[INVESTIGATOR_632044]#    Screening Identification Number  
SMC    Safety Monitoring Committee  
SOP   Standard Operating Procedure  
sPGA    Static Physician Global Assessment  
SSP   Study Specific Procedure  
TBD    To be de termined  
TS    Thymidylate S ynthase  
WBC    White Blood Cell  
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
9 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Protocol Summary  (Synopsis)  
 
Protocol Number: Syntrix -AMT -PSO-201  
 
Objectives:  
 
The purpose of the study is to investigate the efficacy and safety of LD -AMT in adult subjects with 
moderate -to-severe  psoriasis.  LD -AMT is manufactured as a 0.5 mg tablets.  
 
  Primary Objective:  
 
To determine the efficacy of LD -AMT in the treatment of subjects with moderate -to-severe  
psoriasis.  
 
Secondary Objectives:  
 
To determine the safety  of LD -AMT in the treatment of subjects with moderate -to-severe  psoriasis   
 
Design:  
 
A Phase 2, multi -center,  randomized, double -blind, placebo -controlled study enrolling subjects with 
moderate -to-severe  psoriasis to investigate  the safety  and efficacy  of LD-AMT (3 mg (six 0.5 mg 
tablets  overencapsulated in a single capsule ).  Forty -six subjects are randomized to one of two 
parallel treatment  arms: LD -AMT (3 mg) or placebo, in a 1:[ADDRESS_1280194] -treatment phase.  
 
Study P opulation:  
 
Male and female subjects with moderate -to-severe  psoriasis 18 years of age or older.  
 
Sample Size and Randomization:  
 
A total of 46 subjects will be enrolled , 23 in the LD-AMT treatment arm, and 23 in the placebo arm.  
Subjects will be randomly assigned to receive LD -AMT or placebo.  
 
Main Inclusion Criteria:  
 
Male or female subjects aged ≥ [ADDRESS_1280195], defined here as plaque -type psoriasis affecting a body 
surface area of >10% and a PASI of >10.   
 
Study Duration:  
 
Enrollment of [ADDRESS_1280196].  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
10 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   
Endpoints:  
 
Efficacy:  
 
1. Proportion of subjects achieving Psoriasis A rea and Severity Index of 75% (PASI 75) at 
study Day 98 (14 weeks).  
2. Static Physician Global Assessment (sPGA) dichotomized to success or failure  at study Day 
98 (14 weeks).  
3. Proportion of subjects achieving PASI 50 at  study Day 98 (14 weeks).  
4. Mean reduction in the PASI at  study Day 98 (14 weeks).  
5. Proportion of subjects achieving “success” in erythema at study Day 98 (14 weeks).  
6. Proportion of subjects achieving “success” in scaling at study Day 98 (14 weeks).  
7. Proportion of subjects achieving “success” in plaque induration at study Day 98 (14 weeks).  
 
Safety: A dverse events.  
 
Exploratory:  
 
1. Mean hematologic (e.g., hemoglobin, platelets, leukocytes ) and hepatic laboratory (e.g., 
SGOT, SGPT) values over the treatment -phase.  
2. Fraction of abnormal hematologic and hepatic laboratory values over the treatment -phase.  
3. Cumulative incidence of abnormal hematologic and hepatic laboratory values as a function 
of time over the 1 4-week treatment -phase.  
4. Mitochondrial and cytoplasmic folat e metabolism correlates with AMT efficacy and 
toxicity.  
 
Monitoring:  
 
Syntrix Biosystems and its representatives.  
 
Clinical Sites:  
 
Menter Dermatology Research Institute, Dallas, [LOCATION_007]  
Dermatology Associates, Seattle, WA  
Additional sites to be determined.  
 
Sponsor:  
 
Syntrix Biosystems, Inc.  
 
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
11 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  1 OBJECTIVES  
 
The purpose of this study is to determine the efficacy and safety of a new drug to treat psoriasis, 
LD-AMT.   LD -AMT 3.0 mg is administered as a once weekly oral dose to adult subjects with 
moderate -to-severe psoriasis.  
 
1.1 Primary Objective  
 
 To evaluate the efficacy of once weekly 3.0 mg oral LD -AMT administered for 1 4 week s in this 
double -blind, placebo -controlled, trial.    
 
1.2 Secondary Objectives  
 
• To assess the safety of once weekly 3.0 mg oral LD -AMT administered for 14  week s.   
 
• To assess the relationship of each subject’s level of expression of cytoplasmic and 
mitochondrial folate metabolism genes to the subject ’s psoriasis treatment efficacy and 
safety outcomes . 
 
2 BACKGROUND AND SCIENTIFIC RATIONALE  
 
2.1 Introduction  
 
 Psoriasis is a common papulosquamous skin disease that may be associated with a seronegative 
spondyloarthropathy.  Psoriasis affects 2% of the US population, and approximately 10% of these 
subjects have psoriatic arthritis.  Psoriasis has t wo peaks of onset, one in adolescents and young 
adults (at 16 to 22 years of age), and the other in older persons (at 57 to 60 years of age), but the 
range extends from newborn to 100 years.  Men and women are affected equally, but women may 
be affected ea rlier than men.  
 
 US primary care physicians initially see 58% of the estimated 150,000 – 260,000 new cases of 
psoriasis per year, but dermatologists handle 80% of the 3 million office and hospi[INVESTIGATOR_911377]  (Stem '96) . 
 
 Experts agree that psoriatic skin lesions are the result of inflammation in the dermis and 
epi[INVESTIGATOR_911378].  The primary pathologic process is 
believed to arise in the immune system, specifically dysregulation of activated T -cell interactions 
with antigen -presenting cells and overproduction of proinflammatory cytokines.  Evidence for this 
theory derives from the dramatic improvement of severe psoriasis in subjects treated with 
immunosuppressive drugs used in organ transplantation, such as cyclosporine and tacrolimus.  
 
 Although a single disease, psoriasis has several morphologic expressions and a full ran ge of 
severity.  The form that psoriasis takes in a subject depends on a combination of genetic influences, 
environmental factors (e.g., trauma and climate), associated diseases (especially infections), and 
concomitant medications.  Certain drugs, includin g lithium, antimalarials, beta -adrenergic blockers, 
calcium channel blockers, angiotensin -converting enzyme inhibitors, and interferons, have been 
reported to induce psoriasis or aggravate preexisting disease in some subjects.  Emotional stress 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280197] 25 years, methotrexate (MTX) has become a reference standard in the treatment of 
psoriasis. When used fo r the treatment of psoriasis, MTX inhibits the enzymes involved in purine 
metabolism, which leads to an accumulation of extracellular adenosine, a powerful anti -
inflammatory autocoid, and the induction of T cell apoptosis  (Cronstein '93; Genestier '98; Morabito 
'98; Paillot '98; Johnston '05 ). 
 
 Despi[INVESTIGATOR_911379] -to-severe plaque psoriasis, a randomized 
observer -blinded study demonstrated that 15 mg/wk oral monotherapy for 16 weeks in 43 subjects 
(given in three divided doses with a 12 hour interval between dose s) did not achieve PASI 50 in 
30% of subjects, and failed to achieve remission (i.e., > PASI 90) in 60% of subjects (Heydendael 
'03).  The limited response and large interindividual var iability in anti -psoriatic effect of oral MTX 
has been attributed to marked differences in oral bioavailability between subjects, where a poor 
reduction in PASI score has been significantly correlated to poor oral bioavailability of MTX 
(Chladek '98; Chladek '02; Chladek '05) .  While some of these subjects may still respond to 
subcutaneous MTX, development of alternative, more efficacious antifolates, with increased and 
less variable oral bioavailability, is urgently needed.   
 
 Additionally, up to 30% o f subjects with moderate -to-severe plaque psoriasis discontinue oral 
MTX primarily because of intolerance to the drug (Haustein '00) .  Common side effects include GI 
toxicity (nausea, anorexia, stomatitis), marrow suppression and hepatotoxicity.  The latter is of 
particular concern in psoriatic subjects, who may develop life -threatening cirrhosis after chronic 
use.  Depending on the dosage of oral MTX, reports indicate that 10 -47% of subjects with psoriasis 
also exp erience a variety of CNS effects including headache, fatigue, lethargy, disorientation, poor 
memory and agitation (Nyfors '78; Duller '85; Haustein '00; Wollina '01) . 
  
 Thus, an important goal is to develop newer antifolate agents that can increase the proportion of 
subjects that can be maintained at an orally efficacious dose level with less treatment -related 
toxicity . 
 
2.2 Description o f the Study Agent  
 
 The study agent is the Sponsor’s scored biconvex 0. 5 mg LD-aminopterin tablets.  Aminopterin 
(AMT; 4 -amino -pteroylglutamic acid, aminopterin is the International Nonproprietary Name ‘INN’ 
for the sodium salt) is an antifolate in the sam e class as methotrexate (MTX; 4 -amino -N10-methyl -
pteroylglutamic acid, also known as amethopterin, see FIG. 1).  Compared to other antifolates, 
AMT bears the closest structural similarity to folic acid, differing from the natural substrate by [CONTACT_911392] s. 
 
 
 
 
FIG. 1.  The structure of folic acid (FA), AMT, and MTX .  AMT, f irst synthesized in [ADDRESS_1280198] antifolate to exhibit efficacy in pediatric ALL reported in 1948 by [CONTACT_911393] (Farber '48) .  Structurally 
related antifolates, including MTX, were described by [CONTACT_911394] 1948 to 1955.  Folic Acid (FA)  Aminopterin (AMT)  Methotrexate (MTX)  
NHN
NN
NH NH COOHO COOH
NH2O
NHN
NN
NH NH COOHO COOH
NH2NH2
NHN
NN
N NH COOHO COOH
NH2NH2
CH3
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
13 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   
 AMT was marketed by [CONTACT_911395] 1953 and 1964 as a 0.5 mg tablet for the 
indication of pediatric acute leukemia.  It was used off -label to treat over 3,500 psoriatic subjects 
over its 11 year marketed period, being preferred over MTX by [CONTACT_911396] (Rees 
'64).  Lederle discontinued marketing AMT for what ap peared to have been manufacturing 
preferences for MTX.  During the period of their use, the relative toxicity of AMT and MTX were 
never carefully examined by [CONTACT_911397].  
 
 Our more recent preclinical and clinical studies comparing AMT and MTX that are summarized 
in the sections that follow, indicate that AMT: (a) has improved mean oral bioavailability (>90%), 
(b) is more actively and completely taken up by [INVESTIGATOR_100372], (c) accumulates less in the CSF, (d) spares 
erythropoiesis in the marrow, and ( e) spares the liver as measured by [CONTACT_911398].  
 
 These features have spurred renewed interest in testing AMT in the treatment of  psoriasis, as 
well as in a variety of other autoimmune conditions where MTX is used ubiquitously; for example, 
in rheumatoid arthritis, transplantation (solid organ, GVHD), polymyositis, and uveitis  to name a 
few.  Thus, t he results of clinical testing of AMT in psoriasis promise to have far reaching 
implications across clinical disciplines in addition to dermatology . 
 
2.3 Relevant AMT Pre-clinical Studies  
 
2.3.1 Adenosine Release In Vitro  
 
 Interactions between T cells, antigen presenting cells and keratinocytes play a key role in the 
pathogenesis of psoriasis (Prinz '99; Gudjonsson '04) , and a continuous recruitment of mononuclear 
leukocytes is probably required for maintaining active psoriatic lesions (Davison '01) .  The 
inhibition of enzymes involved in purine metabolism by [CONTACT_911399], a powerful anti -inflammatory autocoid that decreases the activation of antigen -
stimulated cells, decreases the expression of adhesion molecules, and possibly induces T cell 
apoptosis (Cronstein '93; Genestier '98; Morabito '98; Paillot '98; Johnston '05) . 
 
 Cronstein et al. reported that MTX induced adenosine release from fibr oblasts in culture with an 
EC50 of 1 nM (Cronstein '91) .  Similarly, L-AMT caused a dose -dependent release of adenosine in 
cultured ma104 cells with an EC 50 of 0.5 nM (data not shown).  These data argue that the anti -
inflammatory mechanism of both AMT and MTX is adenosine rel ease.  
 
2.3.[ADDRESS_1280199] quantified the dose -response relationship of L-AMT and L-MTX (Alcaraz '06) .  
The activities of L-AMT and L-MTX were assessed by [CONTACT_911400] (5 CDI Swiss males per dose 
cohort) four weekly intraperitoneal injections of vehicle, or varying doses of L-AMT or L-MTX 
over the course of a month.  L-AMT and L-MTX diminished, in a dose -dependent fashion, the 
number of leukocytes (predominantly neutrophils) that accumulated in the carrageenan -treated air 
pouches with EC 50 values of 0.0009 mg/kg/wk and 0.04 mg/kg/wk, respectively ( p < 0.001) 
(Alcaraz '06) .  Thus, using a once -weekly dosing regimen that mimics the clinical L-MTX regimen 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
14 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  employed in RA and psoriasis, L-AMT is a 43 -fold more potent anti -inflammatory agent than L-
MTX.    
 
 The dose of L-MTX required to achieve a 50% to 100% response in the air pouch model is 
similar to the dose required clin ically for the treatment of RA or psoriasis (the equivalent of 7 -25 
mg/week in a 70 -kg individual), arguing that the model is a valid indicator of antifolate potency in 
humans.  Based on the dose -response in mice, we predict that the appropriate clinical d ose range of 
L-AMT for treating humans with inflammatory disorders will range from 0.1 -2.0 mg/week in a 70 -
kg individual, which is encompassed by [CONTACT_911401]  (3.0 mg LD -AMT which 
contains 1.5 mg L -AMT) , and is several -fold below the kno wn human maximally tolerated weekly 
dose where mucositis becomes dose -limiting (i.e., ~3 -7 mg/week  L-AMT ).  The weekly AMT 
dosing interval to be used in this study is by [CONTACT_911402].  
Early human experience with the Lederle  tablet further supports these conclusions, where relapse of 
psoriatic lesions after discontinuation of L-AMT was usually seen after 2 weeks (range 2 -8 weeks); 
(Rees '55; Rees '59) . 
 
 The greater p otency of AMT over MTX is mainly due to a greater efficiency of cell uptake of L-
AMT from plasma  (Sirotnak '75; Fry '82; Fry '83) .  Surprisingly, under these same dosage 
conditions, the brains of L-AMT -treated animals contained significantly less L-AMT than the brains 
of L-MTX -treated animals (P ≤ 0.0003), consistent with transport of antifolate across the blood -
brain barrier (BBB) being a concentration dependent phenomenon in mice  (Cole ' 06).  These 
findings in mice paralleled our findings in humans, where weekly doses of 4.0 mg/m2 L-AMT and 
100 mg/m2 L-MTX produced equivalent levels of each drug in erythrocytes, but significantly less 
AMT in the CSF of human subjects (p < 0.0001, two -tailed t -test) (Cole '06) .  This difference in the 
distribution of L-AMT and L-MTX into brain parenchyma and CSF is the basis for the clinical 
hypothesis t hat AMT may decrease the frequency or severity of antifolate -related neurotoxicity by 
[CONTACT_911403], while providing equivalent systemic anti -inflammatory efficacy as MTX.  
 
2.3.3 L-AMT and D -AMT Pharmacokinetics and Toxicity in Dogs  
 
 The oral pharmacokinetics and toxicity of L -AMT and D -AMT were evaluated in 40 beagle 
dogs in escalating doses  (Menter '12) .  The L -enantiomer dose range was 0.02 to 2.4 mg/kg, and the 
D-enantiomer dose range was 0.8 to 82.5 mg/kg.  Doses of the L -enantiomer ranged from a dose 
having optimal anti -inflammatory activity at the low end of the range (data from canine model of 
inflammation), to the minimum lethal single dose at the upper end of the range (Thiersch '49; 
Rieselbach '63) .  Doses of the D -enantiomer were at least 10 -fold larger than the L -enantiomer 
doses to allow for possible poor intestinal absorption of the D -enantiomer.  The C max of L-AMT was 
11- and 6 -fold larger than the C max of D-AMT at doses of 0.8 and 2.5 mg/kg, respectively (p < 
0.001).  The AUC (0-4 h) of L-AMT was 12 - and 6 -fold larger than the AUC (0-4 h) of D-AMT at doses 
of 0.8 and 2.5 mg/kg, respectively (p < 0.001).  There was no dose -dependent trend in T max for 
either L -AMT or D -AMT, and no significant difference between the T max values for L -AMT and D -
AMT.   
 
 Maximum plasma concentration and observed area under the curve were dose -proportional over 
the L -AMT dose range of 0.02 to 0.2 mg/kg and the entire tested D -AMT dose range of 0.8 to 82.5 
mg/kg.  The same pharmacokinetic parameters responded non -linearly to L -AMT doses above 0.2 
mg/kg.  As reflected by [CONTACT_941] 6- to 12 -fold larger maximum plasma concentration and observed area 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
15 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  under the curve of L-AMT compared to D -AMT at identical doses, the exposure is stereoselective 
for the L -enantiomer.  Non -linea rity in pharmacokinetic parameters as a function of L -AMT dose, 
and stereoselectivity for L -AMT over D -AMT together indicate a transporter -mediated component 
in absorption.  
 
 The toxicity of L -AMT and D -AMT was evaluated in each of the above 40 beagle dogs  as 
function of dose through detailed daily clinical and physical observations, and terminal necropsy 
that included gross and histopathologic examinations (Menter '12) .  An additional vehicle group of 
4 beagle dogs served as a negative control.  Beginning three days after the oral administration of L -
AMT, dogs in the 0.8 and 2.5 mg/kg dose groups exhibited severe lethargy, anorexia, vomiting, 
weight lo ss, and diarrhea (including bloody) characteristic of acute antifolate intoxication, with one 
dog found dead and another found moribund and euthanized.  Dogs in the 0.2 mg/kg L -AMT dose 
group exhibited diarrhea five days after dosing.  Dogs in the remainin g 0.02 and 0.08 mg/kg L -
AMT dose groups exhibited no signs of clinical antifolate toxicity.  At necropsy, dogs in the 2.5 
mg/kg L -AMT dose group were found to have multiple red and pi[INVESTIGATOR_911380].  Other histopathologic changes in the 2.5 mg/kg L -AMT dose group 
consisted of mild to moderate bone marrow hypocellularity. Dogs in the remaining L -AMT dose 
groups (lower doses ) had no significant gross lesions or histopathologic findings at necropsy.  
Although the largest D -AMT dose (82.5 mg/kg) was 100 -fold greater than the minimum lethal L -
AMT dose (0.8 mg/kg) and yielded a 7 -fold greater exposure in the plasma, none of the D -AMT 
dose groups exhibited any signs of clinical toxicity and there were no significant gross lesions or 
histopathologic changes at necropsy (Menter '12) . 
 
 In summary oral  absorp tion was stereoselective for the L -enantiomer and D-AMT was not toxic 
at the maximum dose tested (82.5 mg/kg), which was 100 -fold larger than the minimum lethal L -
AMT dose (0.8 mg/kg)  (Menter '12) .   
 
2.3.4 Canine PK Study  
 
 For treatment of inflammatory diseases the Sponsor had prepared a 0.25 mg tablet 
(investigational batch 157I0907) that contained racemic LD -AMT.  For oncology treatment and use 
in previous oncology studies, the Spon sor prepared a 1 mg tablet (investigational batch 116I0604) 
that contains > 99% L -AMT.  Therefore , the Sponsor performed a study in Beagle dogs to compare 
the toxicology and toxicokinetics of these two AMT formulations  (Menter '12) .  The study design 
was a randomized, single dose, two -period cross -over study to compare 0.25 mg LD -AMT tablet 
with a 1.0 mg reference AMT tablet (L -isomer).  Ten dogs were randomized to two parallel arms (5 
per arm) to ingest a 1.0 mg single dose of either the 0.25 mg tablets (4 x 0.25 mg tablets) or the 
reference 1.0 mg tablet (1 x 1.0 mg tablet), and blood specimens were obtained from each dog over 
12 hours.  Seven days later dogs of both a rms were crossed -over and received a single oral 1.0 mg 
dose of the other formulation and again blood specimens were obtained over 12 hours.  The 
endpoint analysis included safety, and measurement of the L and D isomers in plasma by [CONTACT_911404]/MS.  
 
 There w ere no significant AEs, including an absence of gastrointestinal AEs which are the 
earliest symptom of antifolate intoxication.  The concentration profiles of L -AMT in the plasma 
samples following ingestion of the two test formulations (L -AMT formulation a nd LD -AMT 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
16 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  formulation) were indistinguishable.  Importantly, following ingestion of the LD -AMT formulation, 
no D -AMT was detected in any plasma sample.  Therefore, following ingestion of the LD -AMT 
formulation, D -AMT was not absorbed.  Combined, these find ings demonstrate that LD -AMT is 
toxicologically and toxicokinetically indistinguishable from L -AMT, and that the oral 
administration of the LD -AMT does not result in detectable systemic exposure to D -AMT  (Menter 
'12). 
 
2.3.5 Canine Atopic Dermatitis (CAD) Pi[INVESTIGATOR_911381] a chronic, progressive allergic skin disease that results in a profound impairment of 
quality of life due to persistent itching, spontaneous and self -induced skin lesions, secondary skin 
infections, and loss of sleep.  It is associated with IgE antibodies to environmental allergens (Olivry 
'01). 
 
 In an initial 4 -week open -label pi[INVESTIGATOR_4251], followed by [CONTACT_410497] 1 -year extension, AMT 
treatment of CAD was safe and effective (Olivry '07) .  The Sponsor’s 1 mg L -AMT tablet 
(investigational batch 116I0604) was used to treat adult mongrel outpatient dogs with CAD at North 
Carolina State Univers ity.  Subjects were given L -AMT orally at 0.010 mg/kg/week for weeks 1 -4 
(except for one subject who was given 0.015 mg/kg/week at week 4 because of lack of efficacy); 
and escalated as needed to 0.015 or 0.020 mg/kg/wk during the 1 -year extension.  
 
 All 8 dogs that completed the initial 4-week efficacy phase entered the extension phase.  Four 
(50%) completed 16 weeks or more of AMT therapy (mean 19.6 weeks, range 8 -40 weeks).  Seven 
subjects were evaluable for efficacy during the extension phase.  The overa ll efficacy in CAD was 
impressive.  At week 20 for example, all dogs exhibited a greater than 50% reduction in their 
disease assessments, and 66% had greater than a 90% reduction in their disease assessments.  No 
adverse events were observed in any subject s treated for up to 40 weeks with doses up to 0.02 
mg/kg/week, a dose equivalent to 1.5 mg/week L -AMT in a 70 -kg human.  
 
 Together these data indicate that the potency of L -AMT anti -inflammatory activity is similar 
across these species (mice, rats, dogs an d humans).  It is therefore reasonable to predict that 0.25 -
2.0 mg/week L -AMT in a 70 -kg individual will be the appropriate clinical dose range for treating 
human inflammatory disorders.  This is a dose range that is used in this psoriasis study and whose 
safety is supported by [CONTACT_911405].  
 
2.3.6 CAD Dose Ranging Trial  
 
 Following the successful CAD pi[INVESTIGATOR_799], Syntrix sponsored (with support from NIH, National 
Institute of Arthritis and Musculoskeletal Diseases) a multi -center double -blinded, placebo -
controlled, dose -ranging study randomizing 75 dogs to 5 parallel arms ( 15 subjects per arm).  All 5 
arms receive twice weekly oral dosing (one of the two weekly doses in 3 of the 5 arms is a dummy 
placebo dose).  Thus, three arms receive once weekly LD -AMT at 0.01 mg/kg, 0.02 mg/kg or 0.03 
mg/kg, and once weekly placebo.  One  arm receives twice weekly LD -AMT at 0.01 mg/kg, and one 
arm receives twice weekly placebo.  Primary outcome efficacy was assessed at study Day 84 (end 
of 12 weeks).  The Sponsor’s 0.25 mg LD -AMT tablet (investigational batch 157I0907) was used.  
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
17 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   Measure s of toxicity were physical examination, and CBC and blood chemistry tests at Days 14, 
35, 56 and 84.  Seventy -five subjects completed the study; no safety concerns occurred.  Efficacy 
was demonstrated in the 0.02 mg/kg/week do se arm  (published in Zebala JA, Mundell A, Messinger 
L, Griffin CE, Schuler AD, Kahn SJ.  LD-aminopterin in the canine homologue of human atopic 
dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy .  PLoS 
One. 2014 Sep 25;9(9):e108303 ).   
 
2.4 Relevant Human AMT Clinical Studies  
 
2.4.1 Psoriasis Subjects Exposed to Lederle’s L-AMT 0.5 mg Table t 
 
 In the 1950s Lederle produced a 0.5 mg L-AMT tablet.  Safety data were available on 579 
human subjects with psoriasis treated with th is Lederle tablet.  Th e extent of L-AMT  exposure was 
under 1 year in 472 subjects (81.5%), 1 -5 years in 87 subjects (15.0%), and 10 years in 20 subjects 
(3.5%).  An additional 3,[ADDRESS_1280200] one course of Lederle’s L-AMT  tablet.  
 
2.4.2 Oncology Subjects Exposed to AMT in Multi -Agent Therapy 
(CINJALL trial)  
 
 Between March 2001 and Se ptember 2005, 58 children or young adults with acute 
lymphoblastic leukemia (ALL) enrolled in CINJALL: A Phase IIB Trial Of AMT In Multiagent 
Therapy For Children With Newly Diagnosed Acute Lymphoblastic Leukemia at High Risk of 
Relapse.   The CINJALL trial  used the Sponsor’s 1 mg L-AMT tablet ( investigational batch 
116I0604).  The extent of exposure was a median of 98  weeks (range 12 to 140 weeks, N =32 
subjects) or 2,[ADDRESS_1280201] -weeks.  
 
 The CINJALL trial employed adult -equivalent doses of AMT (3.6-7.2 mg  per week)  and MTX 
(77-180 mg per week ).  Once -weekly MTX doses in RA and psoriasis range from 7.5 -30 mg (15 -20 
mg usually), but may extend in some select subjects to [ADDRESS_1280202] exposure  and demonstrated the potential advantages of AMT over MTX when used 
at lower anti -inflammatory doses.  
 
[IP_ADDRESS]  Hematologic Sparing  
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
18 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   Treatment for over 50 weeks with L-AMT 2 mg/m2 (3.6 mg/week in an average adult) caused 
equal suppression of granulopoiesis to L-MTX 40 mg/m2 (72 mg/week in an average adult), but 
resulted in significantly less suppression of erythropoiesis as measured by [CONTACT_911406]  
(p <0.001) .   
 
 Contemp orary experience with MTX in psoriasis provides a useful benchmark for comparison 
with AMT.  In 2001, Wollina et al. reported the chronic toxicities of MTX in 81 subjects with 
psoriasis and psoriatic arthritis treated with 6.5 -40 mg MTX once per week for a bout 100 weeks 
(Wollina '01) .  There were 32 anemic events, the CTC grades were as follows: 4 were g rade 1, 24 
were grade 2 (most common), 3 were grade 3, and 1 was grade 4.  AMT therefore offers the 
potential to make an important clinical improvement in the incidence or severity of anemia AEs.  
 
[IP_ADDRESS]  Hepatic Sparing  
 
 The potential for MTX to cause hepatotoxi city and cirrhosis in psoriasis (Roenigk '98)  and RA 
(Kremer '94)  subjects has been recognized for decades, and has been extensively discussed and 
studied in the literature.  Both dermat ologists and rheumatologists monitor for liver toxicity by 
[CONTACT_911407] (ALT and AST).  The presumed mechanistic model of MTX -
mediated liver injury and corresponding changes in liver blood tests is through intermittent epi[INVESTIGATOR_911382], which in turn result in intermittent rises in serum AST above the normal 
range.  The greater the frequency of the necrosis, the greater probability that liver fibrosis, and 
uncommonly cirrhosis, will occur.  In a study by [CONTACT_911408]. of [ADDRESS_1280203] values significantly increased in subjects as 
a function of the Roenigk grad e, consistent with the mechanistic model (Kremer '96) .  The 
maximum magnitude of abnormal AST values did not correlate with histologic grade. The 
difference in the frequency of abnormal AST elevations between Roenigk Grade I and IIIA was 
8.7% v s. 18.6%, respectively.  
 
 In CINJALL, oral L-AMT 3.6 mg/week in an average adult and L-MTX 72 mg/week in an 
average adult both resulted in elevations of AST:  this happened in 24.4% of the AMT arm, and 
56.6% of the MTX arm (p = 0.0001, Fisher’s exact test) .  The AMT arm also had a significantly 
lower mean value for all AST measurements over the same period (p = 0.0001 ).  AMT thus appears 
to exhibit clinically relevant sparing of the liver compared to MTX, both in terms of the frequency 
and the mean value of  AST elevations.  
 
2.4.3 CNS Sparing Relative to Systemic Compartments  
 
 Neurotoxicity arising during weekly administration of MTX in RA and other autoimmune 
diseases manifests as headache, fatigue, somnolence, vertigo and uncomfortable dissociative -type 
experien ces (i.e., the “post -dosing reaction”).  This neurotoxicity is presumed to be mediated by 
[CONTACT_911409] -affinity intracellular targets such as DHFR.  Penetration of 
AMT and MTX across the blood -brain barrier is thought to be concent ration dependent.  Indeed, of 
41 psoriatic subjects treated with MTX, the 9 subjects who experienced  headache on the day of  
MTX administration had plasma MTX Cmax of 0.76 ± 0.28 µM, whereas those subjects without 
headache had plasma MTX Cmax of 0.24 ± 0.15 µM (Chladek '05) . 
  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
19 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   During CINJALL CSF was collected for analysis of antifolate concentrations.  These date 
demonstrated that CSF MT X concentrations (mean ± SE =  26.3 ± 5.0 nM; n = 45) were 
significantly greater than CSF AMT concentrations (3.56 ± 0.83 nM; n = 64; P<0.0001, two -tailed 
t-test) (Cole '06) .  These data indicate that the penetration of the blood -brain barrier by [CONTACT_911410].  Because AMT is 20 - to 25 -fold more potent than MTX in the 
periphery, lower plasma concentrations of AMT result in lower C SF concentrations, and thus lower 
CNS intracellular AMT.  As a result of these differences in CNS intracellular concentrations of 
AMT and MTX, AMT may cause less neurotoxicity when used in autoimmune indications (Cole 
'06). 
 
2.4.4 Oncology Subjects Exposed to AMT Monotherapy  
 
 AMT monotherapy (Lederle’s L-AMT) exposure was reported in 218 subjects.  The exposure 
periods reported were 0 -12 weeks in 178 subjects (8 1.73%), 13 -28 weeks in 24 subjects (11.0%), 
29-44 weeks in 13 subjects (5.9%), [ADDRESS_1280204] (0.45%) and 61 -76 weeks in 2 subjects 
(0.92%).  An additional 277 oncology subjects were exposed to L-AMT monotherapy (using 
Lederle’s L-AMT) for period s not specified in the primary literature reports, providing for a total of 
495 oncology subjects exposed to L-AMT monotherapy.  
 
2.4.5 AMT Efficacy Experience in Psoriasis  
 
 Two studies with the Lederle L-AMT tablet compared L-AMT and L-MTX (active control) 
using each drug in an equivalent dosing regimen (Rees '61; Strakosch '63) .  The Rees et al. study 
used a crossover design (n=37 in AMT and MTX arms), and the Strakosch study used  a parallel 
dose group design (N=84 AMT, N =36 MTX).  Both studies found that 3.0 -6.0 mg/wk L-AMT 
produced si gnificantly (P < 0.001 both studies, Fisher’s, two -tailed) more successes than L-MTX at 
a 5-fold greater dose.  Analyses of these studies revealed the important observation that increasing 
dose intensity in L -AMT monotherapy beyond about 1.5 mg/wk (given i n 3 divided doses over 3 
days) was associated with an increased incidence of AEs, but no increase in therapeutic successes.  
 
2.4.6 Early (1951) AMT Efficacy Experience in RA 
 
 As was the case in cancer, the first reported use of an antifolate to treat RA employed L -AMT, 
not L -MTX (Ward '85) .  In 1951, Gubner et al. described the use of L -AMT to treat RA in six 
patients (Gubner '51) .  They noted a rapid improvement in arthritis in [ADDRESS_1280205] 7 - to 14 -fold above the dose pred icted to be efficacious in a patient with 
RA.  This study provides evidence that L -AMT is active in RA.  To facilitate comparing the the 
efficacy of L -AMT and L -MTX, we retrospectively evaluated the degree of Gubner’s reported 
improvement using modern ACR criteria.  We found significant improvements in tender joints, 
swollen joints, and physician’s global score of a magnitude similar to those reported for L -MTX 
(Hoffmeister '72; Wilke '80; Wilkens '80; Hoffmeister '83; Thompson '84; Weinblatt '85; Kremer 
'86; Weinblatt '88; Weinblatt '90; Choi '00; Sokka '02; Ruperto '08) .  Gubn er et al. is the only report 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280206] clinical use of L -MTX in RA patients was reported (Ward '85) .  
As L -AMT manufacturing by [CONTACT_911411] 1965, L -MTX became the inevitable 
antifolate of choice for a variety of diseases including RA.  
 
2.4.7 AMT Chronic (> 1 year) T oxicity Experience in Psoriasis and 
Oncology  
 
 The most common AEs associated with chronic AMT therapy include mucositis, bone marrow 
suppression (usually manifesting as leukopenia and thrombocytopenia), nausea, and abdominal 
discomfort.  These can arise a t any time during therapy.  The incidence and severity of AEs 
generally exhibits a dose -response relationship.  However, the schedule of administration can also 
influence toxicity, with divided weekly regimens, compared to once weekly regimens, increasing 
toxicity, presumably due to prolongation of DHFR suppression in normal tissues.  There is no 
evidence that the incidence of toxicity is related to the duration of treatment, cumulative dose or 
efficacy outcomes.  
 
 In all pooled data from clinical trials in  psoriasis (N=427) employing 3 -6 mg/week L -AMT 
given in divided daily doses, leukopenia (defined as WBC <3500/mm3) was seen in 4 subjects, but 
this was never greater than grade 2.  No leukopenia was seen in 21 patients treated chronically with 
1.5 mg/wk L -AMT in a divided dose regimen.  In this protocol all doses are being given as a single 
weekly dose (i.e., less intense than divided doses), and therefore no grade 3 or 4 hematologic 
toxicities are anticipated.  It is possible that grade 1 or grade 2 hemato logic toxicities may occur 
uncommonly to rarely at the dose of 1.5 mg/wk L -AMT (3.0 mg LD -AMT).  
 
2.4.[ADDRESS_1280207] been correlated to poor oral bioavailability (Chladek 
'98; Chladek '02; Chladek '0 5).  Furthermor e, the oral bioavailability of L-MTX in adults has been 
reported to be limited by [CONTACT_911412] 15 mg (Bannwarth '96) .  Thus, 
MTX  non-responders cannot simply increase  the MTX dose.  In contrast to MTX, AMT oral 
absorption does not appear to be limited.  If bioavailability is a limiting variable for oral MTX 
efficacy, then oral AMT may offer a greater response rate than oral MTX.  
 
2.4.9 Syntrix LD -AMT Tablets in PK Study in Psoriasis Subjects  
 
 Syntrix sponsored a PK study in human subjects with psoriasis (Study Registry ID: [REMOVED])  (Menter '12) .  The study was performed at the Dermatology Re search Clinic of the 
Baylor Research Institute (Dallas, [LOCATION_007], [LOCATION_003]) and used Syntrix’s 0.25 mg tablet (composed of 
LD-AMT; investigational batch 157I0907) and 1.0 mg tablet (composed of L -AMT; investigational 
batch 116I0604).  The objective of the study wa s to compare the toxicology and toxicokinetics of 
these two AMT formulations.  The study design was a randomized, single oral dose, two -period 
cross -over study to compare 0.25 mg AMT tablet (LD -AMT) with a 1.0 mg reference AMT tablet 
(L-isomer).  Twenty -two subjects were randomized to two parallel arms (11 per arm) ) to ingest a 
1.0 mg single dose of either the new LD -AMT 0.25 mg tablets (4 x 0.25 mg tablets) or the reference 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
21 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  tablet L -AMT (1 x 1.0 mg tablet), and blood specimens were collected from each sub ject for [ADDRESS_1280208] study drug 
were expected.  The study conclus ions are that the LD -AMT was bioequivalent to the L -AMT.  
Absorption of aminopterin enantiomers was stereoselective for the L -isomer.  The safety database 
for L -AMT tablets can be extrapolated to LD -AMT tablets  (Menter '12) . 
 
2.4.10  Syntrix LD -AMT Tablets in Phase 2 Study in RA Subjects  
 
 The Sponsor completed  a phase 2 trial (Study Registry ID: [REMOVED]) that 
enroll ed 175  MTX -naïve subjects with RA into a 12 -week double -blind placebo -controlled LD -
AMT dose ranging study.  Subjects with active RA (≥ 6 tender and ≥ 6 swollen joints (28 joint 
count)) were randomized to one of three treatments: placebo, LD -AMT (1 mg), or LD -AMT (3 mg) 
in a 1:1:1 ratio.  The primary efficacy en dpoint s were ACR20 and HAQ at Study Day 84 evaluated 
for each cohort in a sequential gate -keepi[INVESTIGATOR_007]/step -down approach.  Secondary endpoints included 
ACR20 (at Study Day 28), ACR50, ACR70, ACR -N, DAS28, DAS28 <3.2, DAS28 <2.6.  Safety 
endpoints were  all AEs,  SAEs and treatment -emergent AEs (TEAEs) , including laboratory 
measurements of serum chemistry and hematology, and the occurrence of dose limiting toxicity  
(i.e., interruption of dosing due to AEs as defined in protocol Section 8.7).   PK analysis was 
performed on 90 of the enrolled subjects.   
 
 The 3.0 mg L /D-aminopterin significantly reduced disease activity by 12 weeks as measured by 
[CONTACT_104706]20 (P=0.021), ACR -N (P=0.030) and DAS28 (P=0.009).  The 1.0 mg dose did not reach 
significance.  Blinded placebo -controlled safety data were obtained and confirm the safety of 
investigati ng 3 mg L/D -aminopterin according to this protocol (see IB).  
 
2.[ADDRESS_1280209] oral medication compared 
to the more expensive anti-cytokine therapi[INVESTIGATOR_014] (e.g., e taner cept, infliximab, a dalimumab).  
 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280210] -of-care.  Subjects enrolled may also benefit from greater fewer treatment 
emergent toxicities than might occur with MTX.  
 
2.6 Rationale  
 
 Lederle marketed L -AMT tablets from 1953 to 1964, and L -MTX tablets from 1955 to the late 
1990s.  The major published studies conducted to evaluate the efficacy of AMT in psoriasis were 
open -label.   These studies showed a significantly greater number of treatment successes with AMT 
than MTX and showed that approximately 55 -65% of a population will reach success after AMT 
treatment.  This protocol is designed to conduct a placebo -controlled double -blinded trial to 
determine if LD -AMT is efficacious and safe in the treatment of subjects with moderate -to-severe  
psoriasis who are naïve to prior MTX treatment.  
 
 The 14 week duration was selected as subjects treated with MTX reach maximum improvement 
in PASI score by 14  weeks (Heydendael '03) .  Similarly, t he time to onset of psoriasis lesion 
“clearing” or “almost clearing” in early pi[INVESTIGATOR_911383] 1 4 weeks as sufficient t o 
observe the majority of  the maximum efficacy.  Hence a 14-week treatment duration was chosen.  
Thus 1 4 weeks will allow responders to declare themselves, and non -responders to be treated within 
the ethical limits established in previous trials for placeb o treatment .    
 
 The weekly dose of LD -AMT for this study is 3.0 mg (1.5 mg of L -AMT).  The selection of this 
dose for efficacy purposes is based on preclinical studies, human studies , and the known relative 
potencies of AMT and MTX.  AMT is an antimetabo lite that is associated with a variety of dose -
dependent toxicities qualitatively similar to those seen with MTX.  In [ADDRESS_1280211] appear, of AMT to be 0.13 
mg/kg/week (wit h no folic acid supplementation) (Ratliff '98) .  For a [ADDRESS_1280212] the MTD of an 
L-AMT single weekly dose is 5.85 mg.  Hence 3 .0 mg L D-AMT (1.5 mg/wk L -AMT), the 
maximum dose in this study, is for all subjects approximately [ADDRESS_1280213] beyond the MTD, included GI disturbances, 
abdominal cramps, diarrhea, hemorrhage, leukopenia, skin changes and alopecia.  In our phase 1 
and 2 oncology studies weekly L -AMT was used to safely treat over 100 adult and pediatric 
subjects , including 20 subjects who were treated for over two years (Ratliff '98; Cole '05; Cole '07) .  
 
 In addition, in our 2010 bioequivalence study in subjects with psoriasis (AMT -PSO-101) LD -
AMT was shown to  be bioequivalent to L -AMT.   These results are further supported by [CONTACT_911413] 
(AMT -RA-202) in adult  subjects with rheumatoid arthritis that has demonstrated the safety of a 
dose of 3.0 mg LD -AMT , without folic acid supplementation,  for 12 weeks.  It is expected that the 
3.0 mg LD -AMT to be used in  this clinical trial will not cause dete ctable toxicities.   
 
 Finally, AMT is known to cause congenital malformations in animals and humans (Thiersch '50; 
Warkany '59; Shaw '68) .  As a result, AMT is handled as an FDA Preg nancy Category X agent, 
requiring effective birth control during treatment and for [ADDRESS_1280214] study 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
23 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  treatment .  The agen t is not used in patients who are pregnant, or until pregnancy can be ruled out in 
women of child -bearing potential.  
 
3 OVERVIEW OF INVESTIGATIONAL PLAN  
 
3.1 Study Design  
 
 This is a  phase 2 , multi -center, randomized,  double -blind, placebo -controlled, clinical trial to 
investigat e the efficacy , safety , of LD -AMT in the treatment of subjects with moderate -to-severe  
psoriasis .  Folate metabolism biomarkers will be study to determine the ir correlation with efficacy 
and safety.  Forty -six subjects will be randomized to one of two parallel treatment arms: LD -AMT 
(3 mg) or placebo, in a 1:1 ratio.  LD-AMT tablets (overencapsulated) or placebo 
(overencapsulated) will be administ ered once week ly for [ADDRESS_1280215] 
study drug administration will be on Day 0.   
 
 Subjects in both treatment groups will receive 14 once weekly oral t reatments.   
 
Group  Treatment Assignment  Route  Schedule  N=[ADDRESS_1280216] study drug administration , and signs a nd symptoms of AEs .  
Blood will be obtained at screening and on Days 0, 14, 42, 70, and 98.  
 
3.2 Primary and Secondary Endpoints  
 
3.2.1 Co-Primary Efficacy Endpoint s 
 
 The co -primary endpoints are:  
 
• The p roportion of subjects achieving Psoriasis A rea and Severity I ndex of 75% (PASI 
75) at study Day 98 (14 weeks).  
 
• Static Physician Global Assessment (sPGA) dichotomized to success or failure at study 
Day 98 (14 weeks).  
 
3.2.2 Secondary Efficacy Endpoints  
 
• Proportion of subjects achieving PASI 50 at study Day 98 (14 weeks).  
 
• Mean reduction in the PASI at study Day 98 (14 weeks).  
 
• Proportion of subjects achieving “success” in erythema at study Day 98 (14 weeks).  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
24 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   
• Proportion of subjects achieving “success” in scaling at study Day 98 (14 weeks).  
 
• Proportion of sub jects achieving “success” in plaque induration at study Day 98 (14 
weeks).  
 
3.2.3 Primary Safety Endpoints  
 
 Any abnormal laboratory values, abnormal vital signs, reported symptoms, or physical 
examination findings will be documented by [CONTACT_911414]. The safety 
assessments will be based on all reported adverse events, and changes in laboratory values from 
baseline.  The severity and relationship to treatment will be recorded for all adverse events. Adverse 
events will be coded for summary an d analysis using standardized preferred terms and system organ 
class.    
 
3.2.4 Exploratory  Endpoints  
 
• Mean hematologic (e.g., hemoglobin, platelet s, leukocyte s) and hepatic laboratory (e.g., 
SGOT, SGPT) values over the treatment -phase  
 
• Folate Metabolism: The evaluation will be based on the comparative analysis of 
mitochondrial localizing and cytoplasmic localizing folate metabolism enzymes  by 
[CONTACT_911415],  e.g., DHFR L1 
(mitochondrial) an d DHFR (cytoplasmic) .  These analyses  will be performed on subject 
RNA isolated from whole blood  obtained at baseline .   
 
3.3 Study Sites  
 
 This trial will be conducted at t wo study sites ( Menter Dermatology Research Institute  (MDRI) , 
Dallas , TX, and Dermatolo gy Associates  (DAS) , Seattle, WA ). All study products will be stored at 
each site under controlled conditions.  
 
3.[ADDRESS_1280217] been enrolled (i.e.,  will have received at least one study drug  dose). Of these, [ADDRESS_1280218] received oral placebo . It is anticipated that 
approximately 50 subjects will be screened to enroll the 46 subjects into the study.  
 
3.5 Estimated Duration/Completion of the Study  
 
 Each subject will be on study for 140 days ( 20 weeks ). It will take approximately [ADDRESS_1280219] is estimated to occur 1 8 months after initial enrollment.  
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
25 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  3.6 Random ization  
 
 The principal investigator (or qualified designees) will be responsible for all study drug 
accounting and distribution .  A randomization list will be generated by [CONTACT_911416] a treatment ratio of 1:[ADDRESS_1280220] will indicate treatment (3.0 mg LD -AMT or placebo) by 
[CONTACT_911417] ( PID# ) (a unique three -digit PID# ). The randomization list will 
remain under control of the Syntrix Pharmaceutical Division .  The Syntrix Pharmaceutical Division 
will ship participant study drug kits to the study sites.  Each participant’s study drug kit will be 
composed of a bottle containing 14 study drug doses (14 capsules), and each bottle  will be  labeled 
with a PID# that corresponds to the study drug treatment assigned by [CONTACT_96913].  The 
label will not indicate the treatment.   Study drug kits will be assigned to participants by [CONTACT_911418]#  as indicated on the bottle label.  The PID# on the study drug kit assigned to a 
participant becomes the participant ’s assigned PID#.  The assigned PID# will  be recorded in the 
Screening Log  with the corresponding participant . Each subject PID#  will be given a site -specific 
two-digit prefix that identifies the site (01 = MDRI; 02 = DAS).   
  
 All subjects who sign consent and who meet all inclusion/exclusion criteria are eligible to 
receive study drug. When eligible subjects pre sent for the Day 0 (baseline ) visit, they are assigned a 
study drug kit.  Study drug kits are assigned to participants by [CONTACT_911419]# as 
indicated on the bottle label.  The PID# on the study drug kit assigned to a participant becomes the 
participant’s assigned PID#.   
 
 A total of [ADDRESS_1280221] will be 
generated  by [CONTACT_911420] a 1:[ADDRESS_1280222] will indicate treatment assignment and 
corresponding PID #.  
  
 Once a subject is found to be eligible and has completed the baseline assessments, they will be 
considered enrolled in the study.  At study Day [ADDRESS_1280223] unblinding of a participant’s treatment assignment, provided it is not a life-
threatening  event, the Investigator will provide the NIAID and Syntrix MMs with sufficient 
information to decide if unblinding should occur.  If the event is life threatening and the MMs are 
not immediately available  to review the request , the investigator can contact [CONTACT_911421] x Medical 
Monitor and that subject’s treatment assignment will be revealed by [CONTACT_911422].  All unblinding of participants will be reported to the 
MMs, the ISM, SCG, the study statistician by [CONTACT_911423].  It is expected that 
given the stoppi[INVESTIGATOR_911384], treatment assignments will 
not need to be unmasked to adequately respond to possible drug -related toxicities.   
 
 Syntrix Pharmaceutical Division  will not release participant treatment assignment s to anyone 
during the study, except a s may be required for safety.  The final unmasking of all subject 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280224] Day of each Study Week (Day 0, Day 7 , Day 
14, etc.).   All efforts should be m ade to maintain an exact weekly administration cycle of study 
drug.  Accuracy to within [ADDRESS_1280225] weekly administration of study drug is missed, then study drug should be administered as 
soon as possible within two days (e.g., the weekly study drug administration is on Wednesday and 
is missed, then the study drug should be administered as soon as possible on Thursday or Friday).  
If the study drug administration is missed for more than two d ays, then that week ’s administration 
should be skipped, and study drug administration should resume on the next weekly cycle day.  This 
is to avoid a temporal spacing of dosings that might precipi[INVESTIGATOR_911385] (i.e. , < 4 day interval 
between doses).   Actu al dates of all study drug administration should be noted in the CRFs.  All 
subsequent study drug administrations should proceed according to the ideal weekly cycle 
referenced back to the date of randomization (Study Day 0), and should not be adjusted to t he 
deviated study drug administration date.   At each study visit, subjects will be given diaries to record 
study drug administration dates.  
 
3.[ADDRESS_1280226], defined here as plaque -type psoriasis affecting a body surface area of >10% 
and a PASI of >10. 
 
 Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet 
light sources during the study.  
 
 Ability to understand and sign written informed consent.  
 
 Hetero sexually active men and women of childbearing potential  must use two  methods  of 
contraception  during the study (20 weeks) a nd for [ADDRESS_1280227] or simultaneously 
in both partners.  The two birth control methods can be (a) 2 barrier methods or (b) a barrier 
method plus a hormonal m ethod to prevent pregnancy.   
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
27 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Barrier methods include: condom (female or male), copper intrauterine device, sponge, or 
spermicide.  
 
If an oral hormonal birth control is being used,  then it should be in  use at least [ADDRESS_1280228] study drug ad ministration .  Hormonal Methods include: any registered and 
marketed contraceptive agent that contains an estrogen and/or a progestational agent, 
including oral, subcutaneous, intrauterine, or intramuscular agents.  
 
 For pre -menopausal women, a negative pre gnancy test, obtained at screening visit  and at 
study visits Week 0, Week 6, Week10, Week 14, and Week 20.  If at any visit during the 
Treatment Phase (see Appendix A) a positive pregnancy test is returned, the subject will be 
discontinued from any further  study drug . 
 
 Negative serology for HIV1/2, hepatitis B and hepatitis C.  
 
 The following screening laboratory blood tests must have the following values, or not 
clinically significant as determined by [CONTACT_978] [CONTACT_73651]: WBC WNL; absolute 
neutrophil  count > lower limit of normal; platelet count WNL; hemoglobin >10.0 g/dL; AST 
< 2.5 x the upper limit of normal.  
 
 Adequate renal function: Creatinine clearance  estimated by [CONTACT_3158] -Gault formula >60 
ml/min  
 
4.2 Exclusion Criteria  
 
Subjects who meet ANY of the following criteria will be excluded from the study (ineligible):  
 
 Known history of hepatitis, HIV infection, interstitial lung disease.  
 
 Greater than moderate a lcohol consumption on a regular basis (moderate consumption for 
females is 1 drink or 1 glass of wine a day; for males is 2  drink s or 2 glass es of wine a day ) 
and unwilling, or unable, to control consumption during the study period.  
 
 Prior use of AMT .  
 
 Use of the se biologic treatments in the timeframes specified:  
 
• Within [ADDRESS_1280229] study drug dose: ustekinumab (Stelara).  
 
• Within [ADDRESS_1280230] study drug dose: any experimental therapy for psoriasis or 
rheumatoid arthritis.  
 
• Within [ADDRESS_1280231] study drug dose: infliximab (Remicade), adalimumab (Humira).  
 
• Within [ADDRESS_1280232] study drug dose: etanercept (Enbrel) . 
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
28 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  • Other biologic therapi[INVESTIGATOR_911386] 5x their half -
life. 
 
 Within 90 days prior to Day 0 and at any time while on study, the use of MTX.  
 
 Within 4 weeks prior to randomization and at any time while on study, use of phototherapy 
(e.g., UVB, narrow band UVB, Goeckerman regimen, Ingram regimen, PUVA), systemic 
medica tions (e.g. acitretin, mycophenolate mofetil, tacrolimus/FK506, cyclosporine A, 
azathioprine, [ADDRESS_1280233] , any systemic 
immunosuppressants), lithium, or any treatments that could affect psoriasis or sPGA  
evaluations.  Subjects are eligible [ADDRESS_1280234] pso riasis evaluations (e.g. , corticosteroids, 
anthralin, vitamin D3/calcitriol and analogues such calcipotriene and tacalcitol, synthetic 
retinoids such as tazarotene, coal tar, and keratolytics such as salicylic acid, lactic acid and 
urea including those con tained in over -the-counter medicated shampoos). Subjects are 
eligible [ADDRESS_1280235] dose of any of the aforementioned treatments was received.  
 
  Note:  Over -the-counter topi[INVESTIGATOR_22918], axilla, 
and/o r genitalia, as needed.  These topi[INVESTIGATOR_911387] [ADDRESS_1280236] (Week 0) study visit.  
 
 Within 2 weeks prior to Study Day 0, or on Study Day 0, or at any time during the study, use 
of any of the following medications that may result in drug/drug interactions with AMT: 
trimethoprim with or without su lfamethoxazole; sulfonamides; sulfonylureas; 
pyrimethamine; triamethamine; salicylates; non -steroidal anti -inflammatory (NSAID) drugs 
including ibuprofen; dipyridamole; colchicine; probenecid; aminoglycosides; theophylline; 
phenytoin; and folinic acid (i.e ., leucovorin).   
 
 Known concurrent malignancy except basal or squamous cell skin carcinoma, or cervical 
carcinoma in situ.  
 
 Concurrent participation in another clinical trial involving experimental treatment within [ADDRESS_1280237] of the trial or pose a morbid risk.  
 
 Investigator’s opi[INVESTIGATOR_160781] a concurrent disease or condition impairs the subject’s ability to 
complet e the trial: includes psychological, familial, sociological, geographical or medical 
conditions.  
 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280238] -feeding.  
 
4.3 Discontinuation of Study Drug  
 
 Subjects with any of the following conditions will be discontinued f rom additional study drug:  
 
• Pregnancy  
 
• Adverse events or concomitant medication that in the opi[INVESTIGATOR_67390] (or designated sub -investigator) would preclude further drug 
 
• Dose limiting toxicity  
 
• Malignancy  
 
 All subjects who have study drug discontinued will be followed until resolution or stabilization 
of the event and  will remain on study for follow -up visits and safety evaluations.  
 
4.[ADDRESS_1280239] Replacement  
 
 Subjects will not be replaced.  
 
5 STUDY PROCEDURES  
 
 A summary of study procedures is provided in Appendix A.  
 
5.1 Consent and Screening Procedures  
 
 Screening evaluations will occur during the 30 -day period prior to Day 0 (i.e., Day -30 to Day -
1).  More than one clinic visit may be required in order to complete all screening evaluations for a 
subject.  Screening labs may be repeated if necessary for p arameters with out of range results (e.g., 
a subject with low hemoglobin may be tested again within [ADDRESS_1280240], as 
long as it is within the 30 -day window ).  The purpose of the screening period is to assure that the 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
30 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  subjects meet  the study entry criteria and that they adequately comprehend the protocol and its 
requirements.  
 
 Prior to the start of screening, the investigator (or study personnel) obtains a signed study 
consent form from each potential study participant. The Screeni ng procedure includes the following 
assessments:  
 
 Explain the study and screening procedures to the subject . 
 
 Review the informed consent form with the subject and obtain his/her signature [CONTACT_911446]. Provide the  subject with a copy of the signed 
consent form.  
 
 Assign the subject a screening identification number (SID#).  This number will be assigned 
sequentially and must be recorded on the sites screening log.  The first two digits of the 
SID# identify the site ( e.g., 01 = Clinic X).  The next three digits identify the subject.  For 
example, the first subject screened, if at the center designated “01”, will be assigned the 
SID# [ADDRESS_1280241] is re -screened th ey 
will be assigned a new SID#.  
 
 Document medical history including smoking history, chronic obstructive pulmonary 
disease, sleep apnea, and drug and alcohol consumption. Rule out any allergies, acute or 
chronic illness that could interfere with study eval uations, cancer or treat ment for cancer 
within [ADDRESS_1280242] 6 weeks.   
Concomitant medications will include contraception that is being used during the trial.  
 
 Assess vital signs : blood pressure, heart rate and temperature . 
 
 Assess psoriasis body surface area involvement  and PASI.  
 
 Perform physical examination .   Measure w eight and height of the subject .  BSA can be 
calculated.  Rule out tattoos or any other dermatological condition that could adversely 
affect the psoriasis  evaluation s. 
 
 Obtain a urine specimen for urinalysis . 
 
 If subject is female of child -bearing potential, perform a urine pregnancy test (beta -HCG).  
 
 Collect approximately 15 ml blood as follows:  
 
• 5 mL anti -coagulated whole blood for CBC, white cell differential and platelet count.  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
31 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   
• 5 mL whole blood for serum chemistry testing. Chemistries to include: BUN, creatinine, 
ALT, AST, total biliru bin, alkaline phosphatase, albumin, and total protein . 
 
• 5 mL whole blood for serology testing. Serology tests to include:  HIV1/2, hepatitis B 
surface antigen (HB sAg), and hepatitis C antibody (HCV AB).  
 
 Obtain a chest X -ray (CXR) (a CXR within the previous 6 months (to date of screening 
visit) may be used instead of performing a new CXR).   
 
 Review CXR and lab results.  Lab results must meet the listed inclusion criteria.  If they do 
not, then the subject is ineligible.  
 
 If subject meets eligibility criteria, then:  
 
• Schedule Study Day [ADDRESS_1280243] 1 hour before their visit as that visit will be one where 
study drug is given.  
 
• Review subject randomization procedure.  Notify central randomization or appropriate 
sponsor designee of new subject to be randomized.  
 
 Complete all CRFs for the visit.  
 
5.2 Week 0 - Day 0 (Baseline) Evaluations  
 
 Subject s who meet all screening evaluation criteria w ill be asked to return to the clinic for the 
baseline visit.  The clinical site coordinator or designee will confirm that appropriate study drug is 
available.   As the subject is randomized and assigned to a study drug treatment, the study drug 
bottle labe l PID# will be recorded on appropriate CRFs and logs as required.  The PID# will be 
composed of the two -digit site number, e.g., 01=Clinic X, followed by [CONTACT_423] -specific three -
digit number that links the study drug provided to the masked study drug tr eatment assigned, e.g., 
01-101.  This PID# must be recorded and linked to the corresponding SID# in the screening log.  
 
Upon arrival, the following evaluations will be completed:  
 
 Perform physical exam as directed by [CONTACT_165544].  
 
 Assess vital signs: blood pressure, heart rate , and temperature . 
 
 Review and record concomitant medications (including alternative and complementary 
treatments) and determine if they are within the prohibited drugs.  
 
 Verify that the subject is compliant with the  contraception requirement.   
 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280244] (beta -
HCG).  A negative result must be confirmed before subject is randomized and study drug is 
administered.  
 
 Perform  psoriasis assessment s (PASI, sPGA, Dermatology Life Quality Index ).   
 
 Collect [ADDRESS_1280245] 1 hour before , and 1 hours after,  the next 
study drug administration (clear liquids are okay).  
 
 Instruct subject on the completion of the study drug diary which will document the AMT 
doses for home administration.   The diary will be used to capture the dosin g of the AMT as 
well as to note any signs or symptoms that may occur in between the site visits.   Provide the 
subject with sufficient blank diaries to last until their next clinic visit.  Ask subject to bring 
their completed diary to their next clinic visi t. The Diary shall be reviewed with the subject 
prior to leaving the study site; clear understanding of how to complete the diary shall be 
documented by [CONTACT_16133], with contact [CONTACT_911424] . 
 
 Remind subject to bring study drug bottle to next (and all) study  clinic visits  to enable study 
drug accounting.  
 
 The completed diary  will be collected by [CONTACT_911425] 14 and a new diary  will be provided, to be collected at the next 
study visi t. 
 
 Complete all CRFs for the visit.  
 
5.3 Week 2 - Day 14 Evaluations  (±2) 
 
Upon arrival, the following evaluations will be completed:  
 
 Review subject diary and record:  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
33 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   
• Concomitant medications (including alternative and complementary treatments) and 
determine if they are within the prohibited drugs.  
 
• Adverse events.  
 
• Study dru g dosing  compliance .  
 
 Verify that the subject is compliant with the contraception requirement .   
 
 Collect blood for CBC and chemistries.  Results must be reviewed before administration of 
study drug on Day 21 so that appropriate study drug dose adjustments (Section 9.1) can be 
made.  
 
 If subject is a woman of child -bearing potential, then obtain a urine  sample and perform a  
pregnancy test (beta -HCG).   A negative result must be confirmed before additional study 
drug is administered.  
 
 If subject remains eligible study drug can be administered.  Subject will be given sufficient 
study drug for home administra tion until subject returns to the clinic for the next scheduled 
visit in [ADDRESS_1280246] 1 hour before  and 1 hour after study drug 
administration (clear liquids are okay).  
 
 Remind subject to bring study drug bottle to next (and all) study clinic visits to enable study 
drug accounting.  
 
 File the completed diaries in the subject source document binder and provide the subject 
with suffic ient blank diaries  to last until their next clinic visit . 
 
 Instruct subject on the completion of the study drug diary which will document the AMT 
doses for home administration.  The diary will be used to capture the dosing of the AMT as 
well as to note any  signs or symptoms that may occur in between the site visits.  Ask the 
subject to bring their completed diary to their next clinic visit. The Diary shall be reviewed 
with the subject prior to leaving the study site; clear understanding of how to complete th e 
diary shall be documented by [CONTACT_16133], with contact [CONTACT_911426] . 
 
 Instruct subject on home administration of study drug on Study Day 21, 28, and 35. 
 
 Complete all CRFs for the vis it. 
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
34 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  5.4 Week 6 - Day 4 2 Evaluations  (±3) 
 
Upon arrival, the following evaluations will be completed:  
 
 Review subject diary and record:  
 
• Concomitant medications (including alternative and complementary treatments) and 
determine if they are within the prohibited drugs.  
 
• Adverse events.  
 
• Study drug dosing compliance .  
 
 Verify that the  subject is compliant with the  contraception requirement.   
 
 If subject is a woman of child -bearing potential, then obtain a urine sample and perform a  
pregnancy test (beta -HCG).   A negative result must be confirmed before additional study 
drug is administered.  
 
 Perform physical exam as directed by [CONTACT_165544].  
 
 Collect blood for CBC and chemistries.  Results must be reviewed before a dministration of 
study drug on D ay 49 so that appropriate study drug dose adjustments (Section 9.1) can be 
made.  
 
 If subject remains eligible study drug can be administered.  Subject will be given sufficient 
study drug for home administration  until subject returns to the clinic for the next scheduled 
visit in [ADDRESS_1280247] 1 hour before and 1 hour after study drug 
administration (clear liquids are okay).  
 
 Remind subject to bring study drug bottle to next (and all) study clinic visits to enable study 
drug accounting.  
 
 File the completed diaries in the subject source docum ent binder and provide the subject 
with sufficient blank diaries to last until their next clinic visit.  
 
 Instruct subject on the completion of the study drug diary which will document the AMT 
doses for home administration.  The diary will be used to captur e the dosing of the AMT as 
well as to note any signs or symptoms that may occur in between the site visits. Ask the 
subject to bring their completed diary to their next clinic visit. The Diary shall be reviewed 
with the subject prior to leaving the study s ite; clear understanding of how to complete the 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280248] on home administration of study drug on Study Day 49, 56, and 63. 
 
 Complete all CRFs for the visit.  
 
5.5 Wee k 10 - Day 70 Evaluations  (±3) 
 
Upon arrival, the following evaluations will be completed:  
 
 Review subject diary and record:  
 
• Concomitant medications (including alternative and complementary treatments) and 
determine if they are within the prohibited drugs.  
 
• Adverse events.  
 
• Study drug dosing compliance .  
 
 Verify that the subject is compliant with the contraception requirement.   
 
 If subject is a woman of child -bearing potential,  then obtain a urine sample and perform a  
pregnancy test (beta -HCG).   A negative result must be confirmed before additional study 
drug is administered.  
 
 Perform physical exam as directed by [CONTACT_165544].  
 
 Collect blood for CBC and chemistries.  Results must be reviewed before administration of 
study drug on Day 77 so that appropriate study drug dose adjustments (Section 9.1) can be 
made.  
 
 If subject remains eligible study drug can be administered.  Subject will be given sufficient 
study drug for home admi nistration  until subject returns to the clinic for the next scheduled 
visit in [ADDRESS_1280249] 1 hour before and 1 hour after study drug 
administration (clear liquids are okay).  
 
 Remind subject to bring study drug bottle to next (and all) study clinic visits to enable study 
drug accounting.  
 
 File the completed diaries in the subject source document binder and provide the subject 
with suffic ient blank diaries to last until their next clinic visit.  
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280250] prior to leaving the study site; clear understanding of how to complete th e 
diary shall be documented by [CONTACT_16133], with contact [CONTACT_911426].  
 
 Instruct subject on home administration of study drug on Study Day 77, 84, and 91.   Inform 
subject that this will  be the last visit where they will be rece iving drug. Subjects will need to 
bring back study drug bottle and all other study related materials at their next visit . 
 
 Complete all CRFs for the visit.  
 
5.6 Week 14 - Day 98  Evaluations  (±3) 
 
Upon arrival, the following evaluations will be completed:  
 
 Review subject diary and record:  
 
• Concomitant medications (including alternative and complementary treatments) and 
determine if they are within the prohibited drugs.  
 
• Adverse events.  
 
• Study drug dosing compliance .  
 
 Verify that the subject is compliant with the contraception requirement.   Remind subject to 
refrain from donating sperm as well as to continue their birth control methods for the next 
90 days (3 months) . 
 
 If subject is a wom an of child -bearing potential, then obtain a urine sample and perform a  
pregnancy test (beta -HCG).    
 
 Perform physical exam as directed by [CONTACT_165544].  
 
 Assess vital signs: blood pressure, heart rate and temperature . 
 
 Collect blood for CBC and chemistr ies.  
 
  Obtain a urine specimen for urinalysis . 
 
 Perform psoriasis assessments (PASI, sPGA, Dermatology Life Quality Index ).   
 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280251] prior to leaving 
the study site; clear understanding of how to complete the diary shall be documented by [CONTACT_75275], with contact [CONTACT_911427].   
 
 Complete all CRFs for the visit.  
 
5.7 Week 17 - Day 119 Evaluations (±4 ) 
 
The following evaluations will be performed by [CONTACT_756] : 
 
 Review subject diary and record:  
 
• Concomitant medications (including alternative and complementary treatments) and 
determine if they are within the prohibited drugs.  
 
• Adverse events.  
 
 File the completed diaries in the subject source document binder and provide the subject 
with sufficient blank diaries to last until their next clinic visit.   Instruct the subject on the 
completion of the diary which will be used to capture any signs or symptoms that may occur 
in between the site visits.  Ask subject to bring their completed diary to their next clinic 
visit. The Diary shall be reviewed with the subject prior to leaving the  study site; clear 
understanding of how to complete the diary shall be documented by [CONTACT_16133], with 
contact [CONTACT_911428].   
 
 Verify that the subject is compliant with the contracepti on requirement.   
 
 Complete all CRFs for the visit.  
 
5.8 Week 20 - Day 1 40 Evaluations (±4)  
 
Upon arrival t he following evaluations will be completed:  
 
 Review subject diary (file the completed diaries in the subject source document binder ) and 
record:  
 
• Concomitant medications (including alternative and complementary treatments) and 
determine if they are within the prohibited drugs.  
 
• Adverse events.  
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280252] (beta -HCG).  
 
 Complete all CRFs for the visit.  
 
5.9 Concomitant Medications  
 
 Subjects may use concomitant medications as permitted by [CONTACT_760].  All medications and 
immunizations, pr escription or non -prescription (including over the counter, alternative, and 
traditional preparations), including any medication used in the treatment of an AE, taken at any time 
from the day of screening evaluation,  through the end of post drug surveillan ce, must be recorded 
on the Concomitant Medication CRF.   
 
 Over -the-counter topi[INVESTIGATOR_22918], axilla, and/or 
genitalia, as needed.  These topi[INVESTIGATOR_248154] 24 hours 
prior to study visits Day 0 and Day 98. Over -the-counter shampoos for the treatment of psoriasis of 
the scalp are also permitted.   
 
5.10 Prohibited Medications and Procedures  
 
 At any time while on study, use of phototherapy (e.g., UVB, narrow band UVB, 
Goeckerman regimen, Ingram regimen, PUVA), systemic medications (e.g. , MTX, 
cyclosporine, biologic therapi[INVESTIGATOR_014], interleukin -2-diptheria -toxin, acitretin, mycophenolate 
mofetil, tacrolimus/FK506, azathioprine, [ADDRESS_1280253] , any systemic immunosuppressants), lithium, or any treatments that could affect 
psoriasis evaluations  are prohibited . 
 
 At any time while on study, any topi[INVESTIGATOR_911388] (e.g. corticosteroids, anthralin, vitamin D3/calcitriol and analogues such 
calcipotriene and tacalcitol, synthetic retinoids such as tazarotene, coal tar, and keratolytics 
such as salicylic acid, lactic acid and urea including those contained in over -the-counter  
medicated shampoos)  are prohibited . Subjects are eligible [ADDRESS_1280254] dose of any 
of the aforementioned treatments was received.  
 
 Within 2 weeks prior to Study Day 0, or on Study Day 0, or at any time during the study, use 
of any of the followi ng medications that may result in drug/drug interactions with AMT: 
trimethoprim with or without sulfamethoxazole; sulfonamides; sulfonylureas; 
pyrimethamine; triamethamine; salicylates; non -steroidal anti -inflammatory (NSAID) drugs 
including ibuprofen; dipyridamole; colchicine; probenecid; aminoglycosides; theophylline; 
phenytoin; and folinic acid (i.e., leucovorin) unless prescribed by [CONTACT_911429].   
 
 At any time while on study elective surgical procedures  are proh ibited.  
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
39 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  5.11 Contraception Requirements for Men and Women  
 
 Aminopterin is embryo -toxic and teratogenic in animals (Bellairs '54; Johnson '64)  and humans 
(Thiersch '50; Meltzer '56; Warkany '59; Shaw '68) , and is reported to have transient effects on 
human sperm.    Men and non -pregnant, nonbreast -feeding women may be enrolled if they are 
considered highly unlikely to conceive.  Highly unlikely to conceive is defined as 1) sur gically 
sterilized (e.g., vasectomy, hysterectomy, tubal ligation), or 2) postmenopausal (a woman who is 
≥45 years of age and has not had menses for greater than 2 years), or 3) amenorrheic for <2 years 
without a hysterectomy and oophorectomy and with a do cumented FSH value in the 
postmenopausal range, or 4) not heterosexually active for the duration of the study, or 5) 
heterosexually active and willing to use two methods of birth control throughout the study starting 
with Day [ADDRESS_1280255] or simultaneously in both partners.  
 
 The two birth control methods can be (a) 2 barrier methods or (b) a barrier method plus a 
hormonal method to p revent pregnancy.  
 
Barrier Methods .  The following are adequate barrier methods of contraception: diaphragm, 
condom (female or male), copper intrauterine device, sponge, or spermicide.  
 
 Hormonal Methods .  Appropriate hormonal contraceptives will include a ny registered and 
marketed contraceptive agent that contains an estrogen and/or a progestational agent, including oral, 
subcutaneous, intrauterine, or intramuscular agents.  If an oral hormonal birth control is used , then it 
should be in use  at least [ADDRESS_1280256] consent.  If 
not used within 10 years  from the time of the study’s last subject clinic visit , the samples will be 
destroyed  by [CONTACT_1034] .   
 
[ADDRESS_1280257].  The clinical investigator o r designee will provide subjects with sufficient study drug at the 
clinic visits .  The Study drug will be shipped under controlled conditions.  A second bottle can be 
used by [CONTACT_911430].  
 
7.2 Labeling  
 
 Study drug will be distributed in bottles with labels that indicate that they contain study drug , 
and with the caution statement “Caution: New Drug – Limited by [CONTACT_911431].”  
 
7.3 Storage  
 
Study drug will be stored at 15 -30°C, protected from light.  The supplies will be accessible 
to authorized personnel only.   
 
7.4 Preparation, Administration, and Dosage of Study Drug  
 
 Study drug or matching placebo will be provided to the site; the treatment period is [ADDRESS_1280258] been completed for that visit.  
 
 Study subjects will be instructed to take their study drug on a designated day each week in 
between the clinic visits; they will be instructed that this  drug schedule is to be kept unless 
otherwise instructed by [CONTACT_16133].  If the dosing schedule is changed or altered in any way 
for any reason, the subject will be asked to  discuss this with the investigative team at the clinic . 
 
7.[ADDRESS_1280259] be completed and r eturned to Syntrix or its designee.  The clinical team member should retain 
a copy of this form for the Investigator’s file.  
 
7.5.[ADDRESS_1280260] or observed by [CONTACT_1275] (or appropriate designee) and laboratory AEs reported as test results.  AEs will be 
recorded on the AE CRF.  Clinical AE relationship to study drug  will be determined by [CONTACT_1275] (or appropriate designee) and recorded on the AE CRF.  Laboratory AE relationship to 
study drug will be determined or recorded on the AE CRFs.  Laboratory AEs considered not 
clinically significant will not be recorde d on the AE CRF.  
 
8.[ADDRESS_1280261] a causal relationship with this treatment.  An AE can be any unfavorable and 
unintended sign (in cluding an abnormal laboratory finding), symptom, or disease, whether or not 
related to the study drug.  
 
8.2.[ADDRESS_1280262] is on study resulting in 
one of the following conditions:  
 
• Death,  
• Life Threatening* (defined as a subject at immediate risk of death at the time of the event),  
• Inpatient hospi[INVESTIGATOR_1081],  
• Congenital anomaly or birth defect,  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
42 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  • A persistent or significant disability/incapaci ty. 
 
 *Any other important medical event that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_059], may be considered a SAE when, based upon medical judgment, the event may 
jeopardize the subject and may require medical or surgical inte rvention to prevent one of the 
outcomes listed above.  Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospi[INVESTIGATOR_3094], or the development of drug dependency or drug abuse.  
 
8.2.3 Unexpected Adverse Event  
 
 Unexpected AEs are those not described in the Investigator’s Brochure.  Expected AEs are those 
described in the IB.  Expected treatment related AEs include, but are not l imited to, grade 1 -2: 
stomatitis, mucositis, nausea, vomiting, gastrointestinal crampi[INVESTIGATOR_007], anemia, leukopenia, 
thrombocytopenia and elevations in liver transaminases.  The IB should be consulted for a 
comprehensive listing.  The duration of such AEs will ty pi[INVESTIGATOR_438877] 1 week.  
 
8.3 Assessment of Adverse Events  
 
 Assessment of clinical AE/SAE must be by [CONTACT_29973], and should 
include the intensity (severity) of the event and the relationship to study drug.  
 
8.3.1 Severity Grading  
 
 The NCI Common Terminology Criteria for Adverse Events v 4.0 (NCI CTCAE v 4.0) will be 
used to categorize AEs and SAEs and to score severity (online at: 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf  ). 
 
8.3.2 Relationship of Adverse Event to Study Drug  
 
 Clinical AE/SAEs must have their relationship to study drug assessed using the following terms 
(NOTE: relationship is not a fac tor in determining what is or is not reported in the study):  
 
• Definitely Related (5)  
 
 There is clear evidence to suggest a causal relationship, and other possible contributing factors 
can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a 
plausible time relationship to drug administration and cannot be explained by [CONTACT_63400]. The response to withdrawal of the drug (dechallenge) should be clinically 
plausible. The event must be ph armacologically or phenomenologically definitive, with use of a 
satisfactory rechallenge procedure if necessary.  
 
• Probably Related (4)  
 
 There is evidence to suggest a causal relationship, and the influence of other factors is unlikely. 
The clinical event,  including an abnormal laboratory test result, occurs within a reasonable time 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
43 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  sequence to administration of the drug, is unlikely to be attributed to concurrent disease or other 
drugs or chemicals, and follows a clinically reasonable response on withdrawa l (dechallenge). 
Rechallenge information is not required to fulfill this definition.  
 
• Possibly Related (3)  
 
 There is some evidence to suggest a causal relationship (e.g., the event occurred within a 
reasonable time after administration of the trial medic ation).  However, the influence of other 
factors may have contributed to the event (e.g., the subject’s clinical condition, other concomitant 
events). Although an adverse drug event may rate only as “possibly” soon after discovery, it can be 
flagged as req uiring more information and later be upgraded to “probably” or “definitely” as 
appropriate.  
 
• Unlikely (2)  
 
 A clinical event, including an abnormal laboratory test result, whose temporal relationship to 
drug administration makes a causal relationship impro bable (e.g., the event did not occur within a 
reasonable time after administration of the trial medication) and in which other drugs or chemicals 
or underlying disease provides plausible explanations (e.g., the subject’s clinical condition, other 
concomita nt treatments).  
 
• Not related (1)  
 
 The AE is completely independent of study drug administration, or evidence exists that the 
event is definitely related to another etiology.  The alternative, definitive etiology must be 
documented.  
 
 Adverse events that are related to psoriasis or common syndromes will be considered related to 
the underlying disease and not to the study agent.  
 
8.4 Diaries (Memory Aids)  
 
 Diaries will be distributed to subjects to aid in documentation of study drug administration, and 
to aid in collection of signs and symptoms of AEs.  Subjects will be instructed to record the date or 
day of study drug administration.  Subjects will also be  instructed to record signs and symptoms of 
AEs.  
 
8.[ADDRESS_1280263] 
be reported by [CONTACT_079] (or designee) directly to Syntrix Pharmacovigilance  within 
24 hours by [CONTACT_166932] .  The reporting sequence for all SAEs, grade 3 and grade 4 
hematologic AEs, and grade 4 hepatic AEs will be as follo ws: 
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
44 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  
 The Principal Investigator (or designee) must report the event immediately (within 24 hours) 
to Syntrix  Pharmacovigilance.  
 
 Syntrix  Pharmacovigilance will then complete and forward an incident report by e -mail, 
containing all relevant information abou t the subject to the Syntrix  MM, NIAID MM , and 
ISM within [ADDRESS_1280264] may continue to 
receive study drug (if more study drug is  scheduled).  
 
 Syntrix  Pharmacovigilance will forward the Syntrix and NIAID MM’s written report and 
recommendation by e -mail to the Principal Investigator [INVESTIGATOR_874] 2 working days of receipt.  
 
 The Principal Investigator [INVESTIGATOR_911389] . 
 
 All SAEs , grade 3 and grade 4 hematologic AEs, and grade 4 hepatic AEs (increased ALT, 
AST, alkaline phosphatase , total bilirubin)  judged to be probably or definitely related to study drug 
will be reported by [CONTACT_911432] [ADDRESS_1280265] wi ll be asked to report the outcome of the pregnancy.  If there is a 
congenital anomaly in the infant, this will be recorded and reported as a SAE for the mother (i.e., 
the study subject).  
 
8.8 Oversight of Data and Safety  
 
 As described in the study DSMP t he Sy ntrix Clinical Group (SCG) in collaboration with NIAID 
medical officers will monitor AMT -PSO-[ADDRESS_1280266]  
 
 The NCI Common Terminology Criteria for Adverse Events v 4.0 (NCI CTCAE v 4.0) will be 
used to score severity grade (online at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-
14_QuickReference_5x7.pdf  or this protocol Appendix C)  
 
9.1.1 Hematologic Adverse Event s (Leukopenia, Thrombocytopenia, 
Anemia)  
 
 For grade 2 leukopenia, grade 2 thrombocytopenia, and grade 3 anemia: study drug is held for a 
maximum of 3 weeks.  Monitoring is performed weekly until the grade 2 leukopenia, grade 2 
thrombocytopenia, or grade 3 anemia AE reso lves.  Then study drug is resumed and the normal 
monitoring schedule is resumed.  If grade 2 leukopenia, grade 2 thrombocytopenia, or grade 3 
anemia continues for > 3 weeks, study drug is withdrawn permanently and leucovorin treatment 
considered.  
 
 For gra des 3 and 4 leukopenia and thrombocytopenia, and grade 4 anemia: study drug is 
withdrawn permanently.  Hematologic labs are retested until normal.  Leucovorin treatment is 
considered for grade 3, and administered for grade 4 AEs  
 
Hematologic AE Algorithm  
Grade  Monitoring Schedule  Study Drug Dosing  Leucovorin Treatment  * 
2 ** Weekly until AE improves  Hold until AE improves (3 weeks 
maximum).  Consider for AEs > 3 weeks  
3*** PI [INVESTIGATOR_911390].  Permanent hold.  Consider  
4 PI [INVESTIGATOR_911390].  Permanent hold.  Yes 
* 10 mg tablet orally once daily  
** Excluding grade 2 anemi a 
*** Excluding grade [ADDRESS_1280267] (SGOT) is used to guide study 
drug dose modifications for hepatoxicity, unless other blood tests are grade [ADDRESS_1280268] monitored weekly until the AE resolves.   
 
Hepatic AE Algorithm  
Grade  Monitoring Schedule  Study Drug Dosing  Leucovorin Treatment  * 
1 No change.   No change  No 
2 No change  No change  No 
3 Weekly until AE becomes grade 2, 
(then resume regular schedule).  After three  grade 3 AE s, then 
study drug is withdrawn.  Consider  
4 Change to weekly until AE resolves.  Study drug is withdrawn.  Consider  
* 10 mg tablet orally once daily  
 
9.1.3 Mucositis/Stomatitis Adverse Events  
 
 For oral mucositis grade 1 a dose suspension is not required.  For mucositis grade 2 that persists 
for ≥ [ADDRESS_1280269] not improved to grade 1, then study drug is withdrawn permanently.  
For persistent lesions of grade 2, or lesions > grade 2, leucovorin treatmen t (10 mg tablet orally 
once daily) can be given.  
 
9.2 Criteria for Interrupting the Trial Based on Dose -Limiting Toxicity 
(DLT)  
 
9.2.[ADDRESS_1280270] from receiving study dru g include:  
 
 Excessive toxicity as delineated by [CONTACT_911433].  
 
 Any clinical adverse event, laboratory abnormality, intercurrent illness, other medical 
condition or situation that, in the opi[INVESTIGATOR_72008]’s Medical Monitor or clinical site 
Investigat or, continued participation in the study would not be in the best interest of the 
subject.  
 
 Study closure due to a decision by [CONTACT_911434].  
 
 Subjects who discontinue study drug because of adverse events should be encoura ged to 
complete visits through D ay [ADDRESS_1280271] -drug surveillance phase of the 
study.   
 
9.2.2 Rules for Suspension of the Entire Study  
 
 Interim rules to halt enrollment until an ad hoc safety review is convened are based on simple 
proportionality,  and are therefore:  
 
Hematologic SAEs:   Grade 3: >2 in 20 enrolled subjects,  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
47 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.       Grade 3: >3 in 30 enrolled subjects,  
     Grade 4: Any.  
 
 Based on the known toxicity profile of the study drug, non -hematologic SAEs related to study 
drug are not likely to occur.  Halting -rules for non -hematologic SAEs related to study drug are 
therefore not specified in this protocol.  Instead, non -hematologic SAEs related to study drug will 
be reported to the Medical Monitor.  The Medical Monitor will assess whether to convene an ad hoc 
review.  The following are provided to the Medical Mon itor as guideline thresholds to convene an 
ad hoc review, but they are not to be binding:   
 
 Non-Hematologic SAEs  related to study drug :  Grade 3: >1 in 30 enrolled subjects,  
         Grade 4: Any.  
 
 The objective of an ad hoc review would be to render a decision as to whether the study should 
continue per protocol, proceed with caution, be further investigated, be discontinued, or the trial be 
modified and then proceed.  Suspension of enrollment for the entire study is a potential outcome of 
a safety revi ew. 
 
 The review of serious, unexpected and related adverse events by [CONTACT_1689], IRB, the 
Sponsor, and regulatory authorities may also result in suspension of further study drug 
administration. The regulatory authorities and the study sponsor ret ain the authority to suspend 
additional enrollment and study drug administration for the entire study as applicable.  
 
10 STATISTICAL CONSIDERATIONS  
 
 This study is a 14 week double -blind, placebo -controlled, study to establish the efficacy of once 
weekly oral  LD-AMT in the treatment of moderate -to-severe  psoriasis.  The co-primary endpoint s 
are 1) the PASI 75 , a composite measure ; and 2) the Static Physician Global Assessment (sPGA) 
dichotomized to success or failure .  The efficacy of LD -AMT will be establishe d by [CONTACT_23992] : 1) 
the proportion of subjects attaining a PASI 75 in the placebo arm and active LD -AMT arm ; and 2) 
the proportion of subjects attaining a sPGA success (a score of 0 or 1)  in the placebo arm and active 
LD-AMT arm .  These comparisons will be made using the Fisher’s exact test. The null hypothesis 
is no treatment effect or equality of proportions, and the alternative hypothesis is that 3 mg LD -
AMT/week is effective at providing a greater proportion of PASI 75 than placebo , or that 3 mg LD -
AMT/w eek is effective at providing a greater proportion of  sPGA success than placebo . 
 
 All descriptive and inferential statistical analyses will be performed using SAS® version 9. 3, R 
version 3.01,  or Strata version [ADDRESS_1280272] of the mean, median, geometric mean (where appropriate), standard deviation, minimum, 
and maximum values. For categorical variables, the number and percentage of each category will be 
displayed for each treatment group. For t he analysis of safety and immunogenicity endpoints, a two -
sided alpha level of 5% will be used. All statistical tests will be two -tailed unless otherwise stated.  
 
 Demographics will be compared among treatment groups using Fisher’s exact test for 
categoric al variables and either a two -sided t -test or the Wilcoxon sum -rank test for continuous 
variables depending on the distribution of the underlying data . Calculations and statistical analyses 
will be described in further detail as part of a statistical analy sis plan.  
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280273], PASI 75 endpoint results were available.  Based on these results the proportion of PASI 75 
achieved in subjects treated with placebo is assumed to be 15%, the proportion of PASI 75 achieved 
in subjects treated with 3.0 mg/week LD -AMT dose is assumed to be 60%, and using a significance 
level ( 2-sided alpha) of 0.05, giving a final sample size of 46 subjects.  This sample size provides 
approximately  85% power to detect a statistically significant efficacy -response. The sample size 
was calculated assuming that a two-sided Fisher’s exact test will be used to analyze the primary 
endpoint.  Moderate loss to follow -up will still result in adequate  power – the power would be 
approximately 80% assuming 10% loss to follow -up. 
 
 Sensitivity Analysis . ICH E9, “It is important to investigate the sensitivity of the sample size 
estimate to a variety of deviations from these assumptions and this may be facilitated by [CONTACT_1541] a 
range of sample sizes appropriate for a reasonable range of deviations from a ssumptions.”  The 
table below shows the sample size sensitivity analysis for a range of deviations in sample size, 
power and treatment effect size assuming a 2 -sided alpha of 0.05 and a placebo PASI75 of 15% 
(power computed using http://hedwig.mgh.harvard.edu/sample_size/fisher/js/fisher.html ). 
 
 N 
PASI75  46 50 54 58 62 
60% 0.85 0.89 0.91 0.93 0.95 
55% 0.76 0.80 0.84 0.86 0.89 
50% 0.[ADDRESS_1280274] one dose of study drug. Statistical 
summaries and analyses of folate metabolism  data will be provided for the ITT and per-protocol 
population, defined as subjects who meet the inclusion/exclusion criteria, receive all 14 study drug 
doses , and complete the Day 98 visit.  
 
 Compar isons will be made using a two sided 0.05 level of significance (α = 0.05). The null 
hypothesis for the comparison is that there is no difference between the treatment groups. Pairwise 
comparison of 3.0 mg LD -AMT and placebo will be analyzed by [CONTACT_3493]’s ex act test for discrete 
binary  comparisons. The primary efficacy analyses for the co -primary endpoints will be analyzed 
utilizing a step -down procedure, which determines statistical significance for the co -primary 
endpoints, while protecting the rate of type  I error.  The order of sPGA and PASI75 analysis in the 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280275] data listings for safety endpoints and the primary metabolism  endpoint 
will be provided in separate appendices to the clinical study report. Separate  listings will be 
provided for each of the treatment groups. All statistical analyses will be performed using SAS® 
version 9.3, R version 3.01, or Stata version 131 or higher.  
 
10.2.2  Disposition of Subjects  
 
 The following information will be summarized for each  treatment group:  
 
• Number of subjects randomized  
 
• Number (%) of subjects receiving all 14 study drug doses  
 
• Number (%) of subjects who discontinued the study and reasons for discontinuation  
 
• Number (%) of subjects in the per -protocol population and reasons  for those excluded  
 
• Number (%) of subjects with at least one protocol deviation  
 
 Protocol deviations will be identified by [CONTACT_632090] (or designee) for the trial.  
 
10.2.3  Demographic Characteristics  
 
 The summaries and statistical analyses of d emographic characteristics will be provided for the 
safety population.  
 
10.2.4  Safety Endpoints  
 
 The summaries and statistical analyses of the safety endpoints will be completed for the safety 
population. Safety endpoints include AEs, any occurrence of dose -limiting toxicity, and changes in 
laboratory values. All AEs will be recorded by [CONTACT_911435], and all AE terms 
will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).  
 
[IP_ADDRESS]  Adverse Events  
 
All AE terms will be coded using MedDRA version 15  or higher. Summaries of the number (%) of 
subjects in each treatment group  with at least one AE, classified according to MedDRA preferred 
term and system organ class, will be provided for:  
 
• All AEs 
• Related AEs 
• SAEs 
Syntrix -AMT -PSO-201, Protocol version 1. [ADDRESS_1280276] one AE using Fisher’s exact test.  
 
 Comparisons of the treatment groups with respect to the incidence of AEs, classified according 
to preferred term and system organ class, will also be performed for all events reported by [CONTACT_2669] 5 
subjects overall.  
 
 The following additional summaries of AEs will also be provided:  
 
• Incidence of AEs by [CONTACT_911436] (mild, moderate, se vere, potentially life -
threatening)  
 
• Incidence of AEs by [CONTACT_8792] (unrelated, related)  
 
[IP_ADDRESS]  Incidence of Dose -limiting Toxicity  
 
 The number (%) of subjects with at least one event of dose -limiting toxicity will be summarized 
for each treatment group.  
 
[IP_ADDRESS]  Laboratory Data  
 
 Summaries of the actual value and change from baseline for all laboratory tests will be provided 
for each study visit. A tabulated summary of laboratory abnormalities by [CONTACT_911437].  
 
[IP_ADDRESS]  Interim Saf ety Analyses  
 
 Interim safety reports will be produced during the study.  
 
[IP_ADDRESS]  Missing Data  
 
 Missing efficacy data, safety data, and folate metabolism data will be recorded as they are  
without imputation of missing values.   
 
10.[ADDRESS_1280277] that includes a 
description of : the investigational plan, includ ing study procedures  that include analysis of gene 
expression levels; specimen storage; risks and benefits;  any study -related costs ; and available 
alternative treatment options . The Investigator or his/her staff will explain the nature of the 
investigation  and the risks involved to each subject prior to enrollment and will obtain written 
informed consent. The subject will also be informed that he/she is free to voluntarily withdraw from 
the study at any time.  
 
11.[ADDRESS_1280278] Access to Source Data/Documents, Study M onitoring, Data 
Collection  
 
 The Investigator will allow representatives of Syntrix (or their designee) to periodically monitor, 
at mutually convenient times during and after the study, all CRFs and corresponding source 
documents for each subject. The Prin cipal Investigator is required to ensure that all CRFs are 
completed for every participant entered in the trial.   It is important that the Investigator or staff is 
available at these visits. The monitoring visits provide Syntrix with the opportunity to eva luate the 
progress of the study, to verify the accuracy and completeness of CRFs, to resolve any 
inconsistencies in the study records, as well as assuring that all protocol requirements, applicable 
regulations, and Investigator's obligations are being fulf illed. The Investigator must maintain all 
source documents (i.e., all information, original records of clinical findings, observations, or other 
activities necessary for the reconstruction and evaluation of the trial.  Examples of these original 
documents and data records include, but are not limited to clinical charts, laboratory notes, 
pharmacy dispensing records, and subject files and records kept at the pharmacy, at the laboratories, 
and other medico -technical departments involved in the clinical trial) , for possible review.  The 
investigational site will provide direct access to all trial -related source documents, other documents, 
and reports for the purpose of monitoring and auditing by [CONTACT_625915], NIH, and regulatory authorities.   
 
 The Syntrix represen tative will record the date of each monitoring visit together with a summary 
of the status and progress of the study. Proposed actions will be confirmed with the Investigator in 
writing.  Telephone contact [CONTACT_911438].  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
52 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   
 Syntrix and representatives will develop study CRFs to ensure that: (1) all information needed 
for the primary and secondary analyses are being collected in a way that will allow accurate and 
comp lete analysis; (2) minimal extraneous information is being collected; and (3) the format is 
efficient for recording, entering and analyzing the data.  
 
 Syntrix or representatives will log and track CRFs to make sure that each CRF page received is 
processed  in a timely manner.  Each table in the database will be carefully checked to make sure 
that all the variables specified on the CRF have been appropriately entered into the database.  Data 
will be cleaned using manual and automated data checks.  Data clean ing queries will be sent to 
investigators , appropriate ancillary staff,  and clinical research monitors .  The status of data queries 
will be monitored.  Syntrix or representatives will ensure that queries are promptly addressed.  
Syntrix or representatives will work collaboratively with clinical monitors to follow -up on data 
clarification, initiating communication with the clinical site when necessary to make sure that data 
problems are promptly addressed.  This process will be used to generate clean data.    
 
 If CRF entries are modified the clinical site staff will annotate the working copy of the CRF 
with who made the change and the date the change was made.  The clinical monitors will verify that 
the clinical trial is conducted and data are generated, docu mented (recorded), and reported in 
compliance with the protocol and the applicable regulatory requirements.  
 
 Syntrix  is responsible for regular inspection of the conduct of the trial, for verifying adherence 
to the protocol, and for confirming the complet eness, consistency, and accuracy of all documented 
data.  
 
11.[ADDRESS_1280279] be initiated and confirmed in writing by [CONTACT_625915], 
and Syntrix will inform the IRB and the modification will not be implemented until approved by [CONTACT_5040].  
 
11.5 Protocol Deviation(s)  
 
 A protocol deviation is any noncompliance with the clinical trial protocol.  Syntrix’s Medical 
Director should be consulted if there is uncertainty as to whether a protocol deviation has occurred.  
The noncompliance may be either on the part  of the subject, the investigator, or the study site staff.  
As a result of deviations, corrective actions are to be developed by [CONTACT_48162].  Protocol deviations will be recorded by [CONTACT_911439] e and final study report.  It is the responsibility of the site to use continuous vigilance to 
identify and report deviations.  Protocol deviations must be sent to the IRB per their guidelines.  
 
11.[ADDRESS_1280280] occurs  as 
permitted by [CONTACT_12212]/GCP Guidelines 4.5.2, 4.5.[ADDRESS_1280281] enrollment and 
removing all investigational products and related study materials from the study site at any time. 
Specific instances, which may precipi[INVESTIGATOR_242960] e such termination at a site, are as follows:  
 
• Deviation from protocol requirements.  
 
• Inaccurate or incomplete data recording on a recurrent basis.  
 
• Unauthorized use of investigational products.  
 
• Delinquent fulfillment of obligation on the part of the Inve stigator with regard to adverse 
reaction reporting, unacceptable subject enrollment, or other responsibilities as outlined 
in this protocol.  
 
11.[ADDRESS_1280282]  one month prior to (i) 
submission of such written materials for publication, or (ii) any proposed oral disclosure to a third 
party.  
 
 The Sponsor shall have the right to comment on such written material or outline; such 
comments shall be considered in goo d faith by [CONTACT_911440].  In the event patentable material is identified in the data, the Sponsor may delay 
publication for up to six months to submit the appropriate patent applications.  Notwithstanding any  
of the above, the Investigator or anyone else working on the Study may not include any confidential 
information in any such publication or disclosure.  
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
54 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.   The International Committee of Medical Journal Editors (ICMJE) member journals have 
adopted a trials -registration policy as a condition for publication.  This policy requires that clinical 
trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_38082].  The ICMJE defines a clinical trial as any research project that 
prospectively assigns human subjects to intervention or comparison groups to study the cause -and-
effect relationship between a medical intervention and a health outcome.  Studies designed for other 
purposes, such as to study ph armacokinetics or major toxicity (e.g., Phase 1 trials), would be 
exempt from this policy.  Syntrix will register this trial in a public trials registry.     
 
 The Investigator is obliged to provide the Sponsor with complete test results and all data deriv ed 
from the study.  Only the Sponsor may make information obtained during and from the study 
available to regulatory agencies, except as required by [CONTACT_5151].  
 
11.[ADDRESS_1280283] be obtained from Syntrix Biosystems before records 
can be destroye d. 
 
11.11  Exclusion of Women, Minorities, and Children (Special Populations)  
 
 Women comprise roughly half of all subjects with moderate -to-severe  psoriasis although there 
tends to be a slightly greater female prevalence in the third decade of life.  This is ref lected in the 
subject population at this study’s clinical sites .  Thus, women are expected to make up roughly half 
of the study population.  
 
 Children and subjects less than [ADDRESS_1280284] party, without prior written approval of the Sponsor.  
  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
55 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Appendix A: Schedule of Study Visits and Procedures  
 [ADDRESS_1280285]’s visit , prior 
to dosing . 
[ADDRESS_1280286]-Treatment 
Phase  
Days  
-30 
to 
0 Day 
 0 Day 
 14(±2) Day 
42(±3) Day 
 70(±3) Day 
98(±3) Day 
119(±4) Day 
140(±4) 
Week 
0 Week 
2 Week 
6 Week 
10 Week 
14 Week 
17 Week 
20 
Randomization   X       
Study Drug Dispensed   X       
Study Drug Administer1  X X X X    
Clinical          
 Informed Consent  X        
 Contraception Requirements2 X X X X X X X X 
 Medical History & Physical Exam  X X3  X3 X3 X3   
 Chest X -ray X        
 Vital Signs  X X    X   
 Assess Psoriasis BSA involvement  X        
  PASI  X X    X   
 sPGA   X    X   
 Dermatology Life Quality Index   X    X   
 Review Patient Diary    X X X X X X 
 Concomitant Medications  X X X X X X X X 
 Adverse Events   X X X X X X X 
Safety Lab Tests          
 CBC with Differential  X  X X X X   
 Chemistries4 X  X X X X   
 HIV1/2, Hepatitis B & C Serology  X        
 UA X     X   
 Pregnancy Test5 X X X X X X  X 
Folate Metabolism Studies          
 Collect Blood6   X       
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
56 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Appendix B.  Calculation of Selected Inclusion and Exclusion Criteria  
 
1.  Inclusion Criteria:  Creatinine C learance  Estimate by [CONTACT_3158] -Gault Formula  
 
     creatinine clearance  = [(140 – age) x weight]  
      72 x SCR  
 
where,   age is in years  
   weight is in kg  
   serum creatinine (S CR) is in mg/dL.  
   creatinine clearance is ml/min  
 
in females, the result is multiplied by 0.85 (Cockcroft '76) .  The Cockcroft -Gault value is not 
adjusted for body surface area (BSA), and in this protocol must be equal to or greater than 60 
ml/min.  An online Cockcroft -Gault calculator is available at: http://nephron.com/cgi -bin/CGSI.cgi  . 
 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
57 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or quoted without prior written authorization from 
Syntrix Biosystems, Inc.   
Appendix C.  Toxicity Grading Scale for Clinical Laboratory Value 1 
 Grade 
Adverse Event  1 2 3 4 
WBC  decreased  < LLN  – 3,000/mm3  <3,000 – 2,000/mm3  <2,000 – 1,000/mm3  <1,000/mm3  
Anemia  Hemoglobin (Hgb) <LLN – 
10.0 g/dL  Hgb <10.0 – 8.0 g/dL  Hgb <8.0 g/dL  Life-threatening 
consequences; urgent 
intervention indicated  
Platelet  count  decreased  < LLN  – 75,000/mm3  <75,000 – 50,000/mm3  <50,000 – 25,000/mm3  < 25,000/mm3  
AST  (SGOT)  increased  > ULN  – 3.[ADDRESS_1280287] >3.[ADDRESS_1280288] >5.[ADDRESS_1280289] > [ADDRESS_1280290] 
ALT  (SGPT)  increased  > ULN  – 3.[ADDRESS_1280291]  >3.[ADDRESS_1280292]  >5.[ADDRESS_1280293]  > [ADDRESS_1280294]  
Alkaline phosphatase 
increased  > ULN  - 2.[ADDRESS_1280295]  > 2.[ADDRESS_1280296]  >5.[ADDRESS_1280297]  > [ADDRESS_1280298]  
Total bilirubin increased  > ULN  - 1.[ADDRESS_1280299] > 1.[ADDRESS_1280300] >3.[ADDRESS_1280301] > [ADDRESS_1280302] 
Hypoalbuminemia  <LLN – 3 g/dL  <3 – 2 g/dL  <2 g/dL  Life-threatening 
consequences; urgent 
intervention indicated  
 
 
 
 
 
1 US Dept. of Health and Human Services, NIH, NCI, Common Terminology Criteria for Adverse Events , Version 4.0 28 May 2009 (v4.03, 14 June 2010) . ULN=upper  limit of normal;  
LLN=lower  limit of normal ; Hgb=hemoglobin;  
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
58 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  References  
 
Alcaraz, M., A. Smith, et al. (2006). "A comparison of systemic efficacy and central nervous system 
exposure to aminopterin and methotrexate in an animal model of inflammation." 
Unpublished.  
Bannwarth, B., F. Pehourcq, et al. (1996). "Clinical pharmacokinetics of low -dose pulse 
methotrexate in rheumatoid arthritis." Clin Pharmacokinet  30(3): 194 -210. 
Chladek, J., J. Grim, et al. (2005). "Low -dose methotrexate pharmacokinetics and 
pharmacodynamics in the therapy of severe psoria sis." Basic Clin Pharmacol Toxicol  96(3): 
247-8. 
Chladek, J., J. Grim, et al. (2002). "Pharmacokinetics and pharmacodynamics of low -dose 
methotrexate in the treatment of psoriasis." Br J Clin Pharmacol  54(2): 147 -56. 
Chladek, J., J. Martinkova, et al. (199 8). "Pharmacokinetics of low doses of methotrexate in patients 
with psoriasis over the early period of treatment." Eur J Clin Pharmacol  53(6): 437 -44. 
Choi, H. K., J. D. Seeger, et al. (2000). "A cost -effectiveness analysis of treatment options for 
patient s with methotrexate -resistant rheumatoid arthritis." Arthritis Rheum  43(10): 2316 -27. 
Cockcroft, D. W. and M. H. Gault (1976). "Prediction of creatinine clearance from serum 
creatinine." Nephron  16(1): 31 -41. 
Cole, P. D., R. A. Drachtman, et al. (2007). "P hase 2B trial of aminopterin in multiagent therapy for 
children with newly diagnosed acute lymphoblastic leukemia." Cancer Chemother 
Pharmacol . 
Cole, P. D., R. A. Drachtman, et al. (2005). "Phase II trial of oral aminopterin for adults and 
children with re fractory acute leukemia." Clin Cancer Res  11(22): 8089 -96. 
Cole, P. D., J. A. Zebala, et al. (2006). "Pharmacodynamic properties of methotrexate and 
Aminotrexate(TM) during weekly therapy." Cancer Chemother Pharmacol  57(6): 826 -34. 
Cronstein, B. N., M. A. Eberle, et al. (1991). "Methotrexate inhibits neutrophil fu nction by 
[CONTACT_911441]." Proc Natl Acad Sci [LOCATION_003]  88: 
2441 -2445.  
Cronstein, B. N., D. Naime, et al. (1993). "The antiinflammatory mechanism of methotrexate. 
Increased adenosine release at inflamed sites diminishe s leukocyte accumulation in an in 
vivo model of inflammation." J Clin Invest  92(6): 2675 -82. 
Davison, S. C., A. Ballsdon, et al. (2001). "Early migration of cutaneous lymphocyte -associated 
antigen (CLA) positive T cells into evolving psoriatic plaques." Exp Dermatol  10(4): 280 -5. 
Duhra, P. (1993). "Treatment of gastrointestinal symptoms associated with methotrexate therapy for 
psoriasis." J Am Acad Dermatol  28(3): 466 -9. 
Duller, P. and P. C. van de Kerkhof (1985). "The impact of methotrexate on psycho -organic 
functioning." Br J Dermatol  113(4): 503 -4. 
Farber, S., L. K. Diamond, et al. (1948). "Temporary remissions in acute leukemia in children 
produced by [CONTACT_911442], 4 -aminopteroyl -glutamic acid (aminopterin)." N Engl J 
Med 238(23): 787 -793. 
Feldkamp, M. and J. C. Carey (1993). "Clinical teratology counseling and consultation case report: 
low dose methotrexate exposure in the early weeks of pregnancy." Teratology  47(6): 533 -9. 
Fry, D. W., L. A. Anderson, et al. (1983). "Analysis of the role of membrane transport and 
polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug 
sensitivity and selectivity." Cancer Res  43(3): 1087 -92. 
Fry, D. W., J. C. Yalowich, et al. (1982). "Rapid formation of poly -gamma -glutamyl derivatives of 
methotrexate and their association with dihydrofolate reductase as assessed by [CONTACT_911443] -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
59 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  liquid chromatography in the Ehrlich ascites tumor cell in vitro." J Biol Chem  257(4): 1890 -
6. 
Genestier, L., R. Paillot, et al. (1998). "Immunosuppressive properties of methotrexate: apoptosis 
and clonal deletion of activated peripheral T cells." J Clin Invest  102(2): [ADDRESS_1280303], et al. (1951). "Therapeuti c suppression of tissue reactivity.  II.  Effect of 
aminopterin in rheumatoid arthritis and psoriasis." Am J Med Sci  22: 176 -182. 
Gudjonsson, J. E., A. Johnston, et al. (2004). "Immunopathogenic mechanisms in psoriasis." Clin 
Exp Immunol  135(1): [ADDRESS_1280304] ein, U. F. and M. Rytter (2000). "Methotrexate in psoriasis: 26 years' experience with low -
dose long -term treatment." J Eur Acad Dermatol Venereol  14(5): 382 -8. 
Heydendael, V. M., P. I. Spuls, et al. (2003). "Methotrexate versus cyclosporine in moderate -to-
severe chronic plaque psoriasis." N Engl J Med  349(7): 658 -65. 
Hoffmeister, R. T. (1972). "Methotrexate in rheumatoid arthritis (abstr)." Arthritis Rheum  15: 114.  
Hoffmeister, R. T. (1983). "Methotrexate therapy in rheumatoid arthritis: 15 years experienc e." Am 
J Med  75 (suppl 7A) : 69-73. 
Johnston, A., J. E. Gudjonsson, et al. (2005). "The anti -inflammatory action of methotrexate is not 
mediated by [CONTACT_911444], but by [CONTACT_911445]." Clin Immunol  114(2): 154 -63. 
Kremer, J. M., G. S. Alarcon, et al. (1994). "Methotrexate for rheumatoid arthritis. Suggested 
guidelines for monitoring liver toxicity. American College of Rheumatology." Arthritis 
Rheum  37(3): [ADDRESS_1280305], et al. (1996). "Signi ficant changes in serum AST across hepatic 
histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy 
for rheumatoid arthritis." J Rheumatol  23(3): 459 -61. 
Kremer, J. M. and J. K. Lee (1986). "The safety and efficacy of th e use of methotrexate in long -
term therapy for rheumatoid arthritis." Arthritis Rheum  29(7): 822 -831. 
Menter, A., B. Thrash, et al. (2012). "Intestinal transport of aminopterin enantiomers in dogs and 
humans with psoriasis is stereoselective: evidence for a mechanism involving the proton -
coupled folate transporter." J Pharmacol Exp Ther  342(3): 696 -708. 
Morabito, L., M. C. Montesinos, et al. (1998). "Methotrexate and sulfasalazine promote adenosine 
release by a mechanism that requires ecto -5'-nucleotidase -mediated conversion of adenine 
nucleotides." J Clin Invest  101: 295 -300. 
Morgan, S. L., J. E. Baggott, et al. (1994). "Supplementation with folic acid during methotrexate 
therapy for rheumatoid arthritis. A double -blind, placebo -controlled trial." Ann Inter n Med  
121(11): 833 -41. 
Nyfors, A. (1978). "Benefits and adverse drug experiences during long -term methotrexate treatment 
of 248 psoriatics." Dan Med Bull  25(5): 208 -11. 
Olivry, T., S. M. Dunston, et al. (2001). "Characterization of the inflammatory infiltr ate during IgE -
mediated late phase reactions in the skin of normal and atopic dogs." Vet Dermatol  12(1): 
49-58. 
Olivry, T., J. S. Paps, et al. (2007). "A pi[INVESTIGATOR_911391] -dose 
aminopterin in the canine homologue of human atop ic dermatitis." Br J Dermatol  157(5): 
1040 -2. 
Paillot, R., L. Genestier, et al. (1998). "Activation -dependent lymphocyte apoptosis induced by 
[CONTACT_372220]." Transplant Proc  30(5): 2348 -50. 
Prinz, J. C. (1999). "Which T cells cause psoriasis?" Clin Exp Dermatol  24(4): 291 -5. 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
60 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Ratliff, A. F., J. Wilson, et al. (1998). "Phase I and pharmacokinetic trial of aminopterin in patients 
with refractory malignancies." J Clin Oncol  16(4): 1458 -64. 
Rees, R. B. and J. H. Bennett (1959). "Further observations on aminopterin for psoriasis." J Invest 
Dermatol  32(1): 61 -66. 
Rees, R. B. and J. H. Bennett (1961). "Methotrexate vs. aminopterin for psoriasis." Arch Dermatol  
83: 970 -972. 
Rees, R. B., J. H. Bennett, et al. (1955). "Aminopterin for psoriasis." AMA Arch Derm  72(2): 133 -
43. 
Rees, R. B., J. H. Bennett, et al. (1964). "Aminopterin for psoriasis: A decade's observation." Arch 
Dermatol  90: 544 -552. 
Rieselbach, R. E., E. E. Morse, et al. (1963). "Intrathecal aminopterin therapy of meningeal 
leukemia." Arch Intern Med  111: 620 -30. 
Roenigk, H. H ., Jr., R. Auerbach, et al. (1998). "Methotrexate in psoriasis: consensus conference." J 
Am Acad Dermatol  38(3): 478 -85. 
Ruperto, N., D. J. Lovell, et al. (2008). "Abatacept in children with juvenile idiopathic arthritis: a 
randomised, double -blind, placeb o-controlled withdrawal trial." Lancet  372(9636): 383 -91. 
Shaw, E. B. and H. L. Steinbach (1968). "Aminopterin -induced fetal malformation." Amer J Dis 
Child  115: 477 -482. 
Sirotnak, F. M. and R. C. Donsbach (1975). "A basis for the difference in toxicity of  methotrexate, 
aminopterin methasquin in mice." Biochem Pharmacol  24(1): 156 -158. 
Sokka, T. and T. Pi[INVESTIGATOR_35807] (2002). "Contemporary disease modifying antirheumatic drugs (DMARD) 
in patients with recent onset rheumatoid arthritis in a US private practice: metho trexate as 
the anchor drug in 90% and new DMARD in 30% of patients." J Rheumatol  29: 2521 -2524.  
Stem, R. S. (1996). "Utilization of outpatient care for psoriasis." J Am Acad Dermatol  35(4): 543 -5. 
Strakosch, E. A. (1963). "A study of folic acid antagonists  in the treatment of psoriasis (aminopterin 
vs. methotrexate vs. aminopterin and a corticosteroid)." Dermatologica  125: 259 -267. 
Thiersch, J. B. and F. S. Philips (1949). "Effects of 4 -amino -pteroylglutamic acid in dogs with 
special reference to megaloblas tosis." Proc Soc Exp Biol Med  71: 484 -490. 
Thiersch, J. B. and F. S. Philips (1950). "Effect of 4 -amino -pteroylglutamic acid (aminopterin) on 
early pregnancy." Proc Soc Exp Biol Med  74: 204 -208. 
Thompson, R. N., C. Watts, et al. (1984). "A controlled two -centre trial of parenteral methotrexate 
therapy for refractory rheumatoid arthritis." J Rheumatol  11(6): [ADDRESS_1280306], J. R. (1985). "Historical perspective on the use of methotrexate for the treatment of 
rheumatoid arthritis." J Rheumatol  12 (suppl 12) : 3-6. 
Warkany, J., P. H. Beaudry, et al. (1959). "Attempted abortion with aminopterin (4 -amino -
pteroylglutamic acid)." AMA J Dis Child  97: 274 -281. 
Weinblatt, M. E. (1985). "Toxicity of low dose methotrexate in rheumatoid arthritis." J Rheumatol 
Suppl  [ADDRESS_1280307] 12 : 35-9. 
Weinblatt, M. E. and A. L. Maier (1990). "Longterm experience with low dose weekly methotrexate 
in rheumatoid arthritis." J Rheumatol Suppl  22: 33-8. 
Weinblatt, M. E., D. E. Trentham, et al. (1988). "Long -term prospective trial of low -dose 
methotrexate in rheumatoid arthritis." Arthritis Rheum  31(2): 167 -75. 
Wilke, W. S., L. H. Calabrese, et al. (1980). "Methotrexate in the treatment of rheumatoid arthritis." 
Clev Clin Q  47: 305 -309. 
Wilkens, R. F., M. A. Watson, et al. (1980). "Low dose pulse methotrexate in rheumatoid arthritis." 
J Rheumatol  7: 501 -505. 
Syntrix -AMT -PSO-201, Protocol version 1. 8    01 December 2018  
 
61 
 
This document is proprietary and is to be used only as authorized. No part is to be reproduced, disclosed to others, or 
quoted without prior written authorization from Syntrix Biosystems, Inc.  Woll ina, U., K. Stander, et al. (2001). "Toxicity of methotrexate treatment in psoriasis and psoriatic 
arthritis --short - and long -term toxicity in 104 patients." Clin Rheumatol  20(6): 406 -10. 
 
 